The role of bacterial pore forming proteins in modulation of host cell function by Culverhouse, Nicole
 The Role of Bacterial Pore Forming Proteins in 
Modulation of Host Cell Function 
 
 
 
 
 
 
Nicole Culverhouse 
MSc Thesis 
October 4, 2016 
 
Supervisor: Professor Timothy J. Mitchell 
Second Supervisor: Professor Ian Henderson
 
 
 
 
 
 
 
 
 
University of Birmingham Research Archive 
 
e-theses repository 
 
 
This unpublished thesis/dissertation is copyright of the author and/or third 
parties. The intellectual property rights of the author or third parties in respect 
of this work are as defined by The Copyright Designs and Patents Act 1988 or 
as modified by any successor legislation.   
 
Any use made of information contained in this thesis/dissertation must be in 
accordance with that legislation and must be properly acknowledged.  Further 
distribution or reproduction in any format is prohibited without the permission 
of the copyright holder.  
 
 
 
Culverhouse i 
 
Abstract 
 Streptococcus pneumoniae is a commensal bacterium found in the nasopharynx. 
Normally this bacterium is harmless but under the right circumstances it can cause invasive 
disease. Understanding the interactions between S. pneumoniae and the various types of host 
cells that it comes in contact with would be invaluable in discerning how this bacterium 
causes invasive disease and aiding in developing treatment options such new vaccines and 
new antibiotics to combat these diseases.  
 The aim of this project was to investigate how pneumolysin, the pore forming toxin 
produced by S. pneumoniae interacts with the host and the effect it has on host cells. A key 
aim of this project was to identify the pathways that are triggered in response to damage 
caused by pores formed from pneumolysin toxin and how these pathways help the cell resist 
cell death and aid in cell repair. Also of interest were the mechanisms by which pneumolysin 
aids in adherence to host cells, as invasion through epithelial and endothelial layers is the first 
step in invasion and subsequently disease.  
 This project resulted in the purification of various forms of pneumolysin including the 
wild type and a nonhaemolytic toxoid. These proteins were quality controlled and their lytic 
effects were tested on lung epithelial cells, a cell type commonly encountered by S. 
pneumoniae in the course of disease. The effects of pneumolysin on the cell tight junction 
proteins E-cadherin and actin was also assessed. Preliminary results showed that lytic 
concentrations of pneumolysin affect the tight junction protein E-cadherin leading to its 
degradation. Different strains of live S. pneumoniae were tested on lung epithelial 
monolayers. It was found that nonencapsulated S. pneumoniae were more proficient at 
adhering and pneumolysin does not significantly increase adherence of the bacteria to lung 
epithelial cells. 
Culverhouse ii 
 
Acknowledgements 
 
 I would like to thank my husband Andrew Culverhouse and my daughters Liliana and 
Kahlan Culverhouse for all of their patience and support during the work, write up and 
corrections of this thesis. 
 I would also like to thank my mom and family for their help and support through this 
process. 
 
 I would like to thank all of the people at the University of Birmingham that helped me 
and gave me the opportunity to study at the IMI. A special thanks to Professor Tim Mitchell 
for all of his guidance and support and for the chance to work in his laboratory. Thanks to all 
the members of the Pneumococcal Research Group for taking the time to teach and help me 
throughout my time at the IMI. Lastly, I would like to thank the Henderson lab for hosting 
me for the last few months of my experimental work.  
Culverhouse iii 
 
Table of Contents 
Abstract .............................................................................................................................................. i 
Acknowledgements ........................................................................................................................... ii 
Table of Contents ............................................................................................................................. iii 
Abbreviations ................................................................................................................................... vi 
Chapter 1: Introduction ...................................................................................................................... 1 
1.1 Streptococcus pneumoniae ....................................................................................................... 1 
1.1.1 Carriage and Disease ......................................................................................................... 1 
1.2 Pneumolysin ............................................................................................................................ 2 
1.2.2 Release of Pneumolysin .................................................................................................... 4 
1.2.3 Effects of Pneumolysin on the Host ................................................................................... 4 
1.2.4 Pneumolysin and the Host Immune System ....................................................................... 4 
1.3 Tight Junctions and E-cadherin ................................................................................................ 5 
1.3.1 Pneumolysin and Tight Junction Integrity .......................................................................... 8 
1.4 Aims and Objectives .............................................................................................................. 11 
Chapter 2: Methods and Materials ................................................................................................... 14 
2.1 Protein Purification ................................................................................................................ 14 
2.1.1 Purification of pneumolysin ............................................................................................ 14 
2.1.2 Protein purification of Δ6PLY and eGFPΔ6PLY ............................................................. 15 
2.1.3 Generation of Negative Vehicle for Purified Pneumolysin ............................................... 15 
2.1.4 Generation of Nickel Elution Protein for Purified Pneumolysin ....................................... 16 
2.2 Cell Based Assays.................................................................................................................. 16 
2.2.1 Haemolytic assay ............................................................................................................ 16 
2.2.2 Lactate Dehydrogenase (LDH) Assay .............................................................................. 17 
2.2.3 MTT (3-(4, 5-Dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide) Assay ................. 17 
2.3 Host-pathogen interactions ..................................................................................................... 18 
2.3.1 Growth curves ................................................................................................................. 18 
2.3.2 Transformation of E. coli ................................................................................................ 19 
2.3.3 Plasmid DNA preparation ............................................................................................... 19 
2.3.4 Transformation of S. pneumoniae .................................................................................... 19 
2.3.5 Extraction of genomic DNA from bacteria ...................................................................... 20 
2.4 Exposure of A549 Lung Epithelial Cells to GFP tagged toxin................................................. 20 
2.4.1 Exposure of A549 Lung Epithelial Cells to eGFP tagged PLY toxin ................................ 20 
Culverhouse iv 
 
2.4.2 Exposure of A549 Lung Epithelial Cells to eGFP tagged Δ6PLY toxin with Live Cell 
Imaging ................................................................................................................................... 21 
2.5 Immunofluorescence Microscopy ..................................................................................... 22 
2.5.1 Toxin exposure following by staining for cellular actin .................................................... 22 
2.5.2 E-cadherin staining ......................................................................................................... 23 
2.6 Western blotting for E-cadherin ............................................................................................. 24 
2.7 Adherence Assay ................................................................................................................... 25 
Chapter 3: Results ........................................................................................................................... 27 
3.1 Protein purification ................................................................................................................ 27 
3.1.1 Purification of the pore forming protein pneumolysin ...................................................... 27 
3.1.2 Generation of pneumolysin negative vehicle .................................................................... 30 
3.1.3 Haemolytic assays to test the functionality of purified, recombinant PLY ........................ 32 
3.1.4 Purification of Δ6PLY..................................................................................................... 35 
3.1.5 Δ6eGFPPLY ................................................................................................................... 37 
3.2 Cell Based Assays.................................................................................................................. 38 
3.2.1 LDH and MTT assays in L929 fibroblast cells ................................................................. 38 
3.2.2 LDH assays in A549 lung epithelial cells ........................................................................ 40 
3.3 Determining sublytic pneumolysin concentrations in A549 lung epithelial cells ..................... 41 
3.3.1 Confocal microscopy using eGFPPLY ............................................................................ 41 
3.4 Effects of PLY and Δ6PLY toxoid in A549 lung epithelial cells ............................................. 43 
3.4.1 Live cell microscopy using Δ6eGFPPLY......................................................................... 43 
3.4.2 Immunostaining of F-actin, E-cadherin and eGFP labelled toxin in A549 cells ................ 45 
3.4.3 Western blotting for E-cadherin and actin in A549 whole cell lysates .............................. 49 
3.4.4 Effect of pneumolysin and polysaccharide capsule on adherence of S. pneumoniae to A549 
lung epithelial cells .................................................................................................................. 50 
3.5 Optimisation of the Experiment Environment for Host-Toxin Interactions .............................. 52 
3.5.1 Introduction of pJWV25 plasmid into S. pneumoniae ...................................................... 52 
3.5.2 Production of Chemically Defined Media and Preliminary Growth Curves ...................... 53 
Chapter 4: Discussion ...................................................................................................................... 56 
4.1 Purification of proteins........................................................................................................... 56 
4.2 Determining sublytic concentration of WTPLY ...................................................................... 60 
4.3 Cytotoxic effects of PLY and Δ6PLY toxoid in A549 lung epithelial cells.............................. 61 
4.4 Effects of PLY on E-cadherin and F-actin in A549 lung epithelial cells .................................. 62 
4.5 Effect of pneumolysin and capsule on adherence of S. pneumoniae to A549 lung epithelial cells
 .................................................................................................................................................... 65 
Culverhouse v 
 
4.6 Host-Pathogen Interactions and Generation of a Fluorescently Tagged Pneumolysin .............. 67 
4.7 Summary ............................................................................................................................... 70 
4.8 Future Work .......................................................................................................................... 71 
Appendix I Recipes ......................................................................................................................... 72 
Appendix II Strains Used in this Study ............................................................................................ 74 
References....................................................................................................................................... 75 
 
  
Culverhouse vi 
 
Abbreviations 
PLY = pneumolysin 
CDC = cholesterol dependent cytolysins 
LPS = lipopolysaccharide  
TLR = toll like receptor 
WTPLY = wild type pneumolysin 
GFP = green fluorescent protein 
eGFP = enhanced green fluorescent protein 
DPBS = Dulbecco’s phosphate-buffered saline 
PBS = phosphate-buffered saline 
WT = wild type 
x g = g force 
CFU = colony forming unit 
ECL = enhanced chemiluminescence 
E-cadherin = epithelial cadherin 
VE-cadherin = vasoendothelial cadherin 
kDa = kilo Dalton 
Å = angstrom 
TGF-β1 = transforming growth factor beta 1 
PKC-α = protein kinase C alpha 
ROCK = Rho associated protein kinase 
TNF-α = tumour necrosis factor alpha 
TIP peptide = synthetic peptide derived from TIP motif of (TNF-α) 
RPMI = Roswell Park Memorial Institute media developed by Moore et al. 
DMEM = Dulbecco’s Modified Eagle Medium 
FCS = fetal calf serum 
CO2 = carbon dioxide 
OD600 = optical density, absorbance at 600nm 
EDTA = ethylenediaminetetraacetic acid 
dH2O = distilled water 
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PFA = paraformaldehyde 
DAPI = 4’, 6-diamidino-2-phenylinodole, fluorescent nuclear stain ex/em 358/461 
Δ6PLY = pneumolysin mutant generated by an amino acid deletion of alanine 146 and 
arginine 147 
Δ6eGFPPLY = pneumolysin mutant generated by an amino acid deletion of alanine 146 and 
arginine 147 with an added conjugation to enhanced green fluorescent protein 
BSA = bovine serum albumin 
SDS = sodium dodecyl sulphate 
SDS-PAGE = sodium dodecyl sulphate polyacrylamide gel electrophoresis 
HRP = horseradish peroxidise 
TBST = Tris-buffered saline plus Tween-20 
LDH = lactate dehydrogenase 
PdB = Pneumolysin with amino acid change W to F at position 433. Also known as F433 
DTT = dithiothreitol 
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Chapter 1: Introduction 
1.1 Streptococcus pneumoniae 
 First isolated in 1881 by both Louis Pasteur and George Sternberg independently, 
Streptococcus pneumoniae (pneumococcus) is a Gram positive, diplococcus with fastidious 
nutritional requirements [Murray 2009; Mitchell 2010]. The pneumococcus is a facultative 
anaerobe that has the ability to utilize various types of carbohydrates using oxygen where 
available or in the absence of oxygen it can switch to generating ATP via the lactic acid cycle 
[Murray, 2009]. However, as this bacterium lacks catalase which is required to break down 
the large amounts of hydrogen peroxide generated when performing aerobic respiration, in 
order to grow and survive, the pneumococcus requires enriched media supplemented with a 
catalase source, such as blood [Murray, 2009; Pericone 2003].  
 S. pneumoniae has a genome of about 2 million base pairs with approximately 2200 
total genes [Tettelin, 2001]. This bacterium has high genetic variability with only about 1400 
of its total genes being shared by all serotypes (Hiller, 2007). One reason for this high 
variability is the naturally transformable nature of S. pneumoniae. The pneumococcus 
undergoes competent stages during its life cycle and can readily incorporate external DNA 
into its genome from closely related species [Johnsborg, 2009; Guiral, 2005]. This activity is 
thought to help the organism in combating host defences and therefore aiding in its capacity to 
cause human disease [Guiral 2005]. 
1.1.1 Carriage and Disease 
 Streptococcus pneumoniae is a common inhabitant of the nasopharynx of humans, 
especially children [Mitchell, 2010]. To colonize this part of the human body, S.pneumoniae 
utilizes surface proteins called adhesins to allow it to attach to human epithelial cells. Once 
attached, this bacterium colonizes the nasopharynx as a normal part of the human flora and 
protects itself from being physical removed by mucus using its capsule structure [Murray, 
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2009; Nelson, 2007]. Although S. pneumoniae is usually an asymptomatic occupant of the 
human body it has the capacity to cause invasive disease [Mitchell, 2010]. The pneumococcus 
causes a variety of illnesses prevalent in children and the elderly including pneumonia, 
bacteraemia, meningitis and otitis media [WHO, 2012]. An estimated 1 million children die of 
pneumococcal disease every year with the majority of fatalities occurring in developing 
countries. However, a significant disease burden can be seen in developed countries such as 
the United Kingdom [WHO, 2013]. There is an estimated 40,000 hospitalizations and over 
100,000 general practitioner consultations regarding pneumococcal diseases such as 
pneumonia and otitis media reported to Public Health England every year from England and 
Wales [Public Health England, 2013].  
The ability for the pneumococcus to cause invasive disease is due to a variety of 
virulence factors possessed by the bacterium [Murray, 2009]. These virulence factors include 
the pore forming protein pneumolysin, the polysaccharide capsule, LPXTG-anchored surface 
proteins, the pilus, choline binding proteins, lipoproteins and various other surface proteins 
[Mitchell, 2010]. 
1.2 Pneumolysin 
 Pneumolysin (PLY) is the pore forming toxin produced by S. pneumoniae and can be 
found in almost every clinical isolate of this bacterium. This toxin enables the pneumococcus 
to lyse all cells with cholesterol containing membranes aiding the ability of the bacterium to 
cause invasive disease (Mitchell 2010; Mitchell 2006). PLY belongs to the family of proteins 
known as the cholesterol dependent cytolysins (CDC) (Marriot, 2008). This family of proteins 
mainly includes toxins expressed from a variety of Gram positive bacteria (Cassidy, 2013; 
Marriot, 2008). The CDC proteins are all soluble monomers that form large, β-barrel pores 
once they bind to their host cell membrane; however, each one plays a different role in 
invasive disease that is specific to the bacterium that produces it (Cassidy, 2013). Some 
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examples of CDCs are listeriolysin O from Listeria monocytogenes, streptolysin O from 
Streptococcus pyogenes and perfringolysin O from Clostridium perfringens (Gonzalez, 2007). 
PLY is a 53kDa asymmetric protein with four domains that forms large pores of 35 to 
50 monomeric units with diameters in the size range of 250 to 300Å [Marshall, 2015; 
Morgan, 1994; Cassidy, 2013]. The mechanism by which PLY forms pores remains 
undetermined but there is a proposed mechanism which is widely accepted. This mechanism 
of pore formation begins with the monomer of PLY binding to the host cell membrane, PLY 
monomers then aggregating together forming a ‘pre-pore’ complex. The monomers then 
undergo a change in conformation allowing for insertion into the host cell lipid bilayer 
(Marriott, 2008; Tilley, 2005). Tilley et al. 2005 used cryo electron microscopy to help 
support this method of pore formation by taking snapshots of various conformational changes 
of PLY when it interacts with liposomes. 
 
 
Figure 1.1. Representation of the major 
stages of pore formation. A) Toxin monomer 
binding to host membrane. B) Monomers 
aggregate together forming a ‘pre-pore’ 
complex C) Conformational change of the 
toxin monomers inserting into the host 
membrane. Figure obtained from Tilley et al. 
2005. 
Additional support came when PLY was crystallized in two separate studies 
(Lawrence, 2015; Marshall, 2015). The crystal structure supports the theory of the pre-pore 
complex as the monomers in the crystal pack side by side and the intermolecular contacts are 
critical for the haemolytic function of PLY (Marshall, 2015). Two potential binding sites were 
proposed in the Lawrence et al study (2015). One potential site is located at the base of the 4
th
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domain while the other is located at the interface of the 3
rd
 and 4
th
 domains at the opposite end 
of domain 4 (Lawrence, 2015). The exact binding site and mechanism is still to be confirmed.  
1.2.2 Release of Pneumolysin 
The mechanism of release of pneumolysin from the bacterial cytoplasm is still 
undetermined as it lacks an N-terminal secretion sequence (Marriot, 2008). This sequence 
which is present in all of the other CDC family members is essential for the transport of these 
toxins out bacterial cells while leaving the cell intact (Benton, 1997). PLY is known to be 
released from S. pneumoniae when the bacteria undergoes autolysis during the late log phase 
of its growth cycle, however this is not the only mechanism of release as other studies have 
shown haemolytic effects on red blood cells in LytA and LytC autolysin negative mutants 
(Benton, 1997; Balachandran, 2001; Guiral, 2005).  
1.2.3 Effects of Pneumolysin on the Host 
 Pneumolysin affects the host in both lytic and sublytic concentrations causing the 
creation of reactive oxygen intermediates, activation of the immune system and activation of 
various signalling pathways (Mitchell, 2010; Cockeran, 2001; Marriot, 2008). 
1.2.4 Pneumolysin and the Host Immune System 
The activation of the host immune system by PLY is suggested to aid the bacterium in 
its colonization of the nasopharynx. As there are many species competing for this niche 
environment, the ability of S.pneumoniae to trigger the host immune system can give the 
pneumococcus a competitive advantage by clearing other bacterial species while it utilizes its 
polysaccharide capsule to avoid being cleared itself (Marriot, 2008). 
PLY activates the classical complement pathway of the immune system by binding the 
Fc portion of immunoglobulin and C1q (Paton, 1984; Mitchell, 1991). At the same time, an 
innate immune response is triggered in the host when PLY binds to the Toll like receptor 4 
(TLR4) which is found on the cell surface of macrophages (Srivastava, 2005; Koppe 2012). 
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Although TLR4 is more commonly associated with LPS in Gram negative bacteria, in vivo 
studies using TLR4 deficient mice found an increased susceptibility to pneumococcal 
colonization, higher bacterial loads and a dramatic overall reduction in the ability of the host 
to cope with pneumococcal infection suggesting that TLR4 also plays a role in the infection 
process of S. pneumoniae (Koppe, 2012; Malley, 2003). The interaction of pneumolysin with 
TLR4 has been suggested to activate the TLR4-dependent caspase-1 pathway. This pathway 
leads to the production of caspase-1 cytokines such as interleukin (IL)-1α, IL-1β and IL-18 
which are involved in cell signalling (Shoma, 2008; Koppe, 2012). 
PLY also activates T-cells which contribute to the host’s innate and adaptive immune 
responses. T-cells have been shown to contribute early in the immune response by clearing S. 
pneumoniae (Koppe, 2012; Kadioglu, 2004; Rossum 2005). 
Various cell signalling pathways are activated in the presence of PLY. However, 
whether a pathway is activated by sublytic concentrations of PLY or whether the pathway is 
triggered by the after effects of host cell lysis is often hard to determine. One such example is 
the p38 MAPK pathway. When pneumolysin binds to cholesterol, the cell membrane 
depolarizes too early causing the formation of micropores in the plasma membrane (Iliev, 
2007). The micropores are large enough that calcium ions can enter the cell resulting in the 
activation of various signalling cascades such as the p38 MAPK pathway (Iliev, 2007; Ratner, 
2006). However, calcium influx is not the only trigger for the p38 MAPK pathway, as this 
pathway has also been shown to activate in response to the osmotic stress when PLY forms a 
mature pore and water subsequently floods into the cell (Ratner, 2006).  
1.3 Tight Junctions and E-cadherin 
 One of the first defences the body has against pathogens is epithelial cell barriers. In 
order to form a functional seal to prevent invasion into the bloodstream or surrounding 
tissues, epithelial barriers require both tight junctions and adherens junctions. The interactions 
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of proteins in these junctions, such as E-cadherin and catenins and their subsequent 
interactions with the actin cytoskeleton are critical for the successful cell to cell adhesion, 
intracellular and intercellular signalling (Tian, 2011).  
Cadherins are a family of cell surface proteins that function in signalling and 
regulation of a variety of cellular processes including cytoskeleton remodelling, Rho GTPase 
cascades, gene expression, membrane trafficking, growth factor signalling, cell motility and 
proliferation (Saito, 2012; Tian, 2011). The cadherin family of proteins is further split into the 
classical cadherin group and the desmosomal cadherin group (Saito, 2012). The classical 
cadherins are then categorized as either type I cadherins or type II cadherins. Type I cadherins 
include epithelial (E), placental (P) and neural (N) cadherins. Type II cadherins include 
vasoendothelial (VE), kidney (K) and muscle (M) cadherins (Saito, 2012; Tian, 2011). The 
classical cadherin, known as E-cadherin or CDH1, is an essential component for the creation 
and maintenance of a solid and polarized epithelium. The classical cadherins share a single 
transmembrane structure that utilizes calcium ions to aid in cell to cell adhesion within tissues 
(Tian, 2011). The cytoplasmic side of the classical cadherins bind to p120 catenin and β-
catenin which are members of the catenin family of proteins (Menke, 2012; Saito 2012). 
 
Figure 1.2: Structure of classical cadherins and their 
binding partners. Figure obtained from Saito et al. 2012. 
Interactions between catenins and cadherins play a 
role in cell to cell adhesion and epithelial morphology. 
The coupling of β-catenin and E-cadherin is one example. 
The E-cadherin/β-catenin complex is a critical component 
in the formation of adherens junctions. If this complex 
breaks down, for example if β-catenin is phosphorylated, cell-cell adhesion decreases which 
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in turn leads to increased invasion and migration of cells (Tian, 2011). The breakdown in the 
E-cadherin/β-catenin complex has been linked to transforming growth factor (TGF)-β1 which 
is known to act via Snail and/or Smad3 causing a disassociation of the E-cadherin/β-catenin 
complex (Shao, 2011). TGF-β1 and its role in barrier disruption has been further investigated 
for its role in bacterial infection in studies such as Beisswenger (2007) and Clarke (2011) 
which linked this growth factor its downstream pathways to S. pneumoniae transepithelial 
migration (Beisswenger, 2007; Clarke, 2011; Tian, 2011). Whether the bacterial trigger for 
TGF-β1 signalling is via TLR2, which would point to a reaction to bacterial cell wall 
components, or TLR4, which may indicate the involvement of pneumolysin is still in debate 
(Koppe, 2012; Clarke, 2011; Beisswenger, 2007). A study by Inoshima et al. (2011) exposed 
A549 lung epithelial cells to the small bacterial pore forming protein α-hemolysin from S. 
aureus. This study found a few pore forming toxins led to the degradation of tight junctions in 
A549 lung epithelial cells by utilizing the host zinc metalloproteinase ADAM10 as a receptor 
leading to the cleavage of E-cadherin. These results suggest that pore forming toxins may 
manipulate innate host pathways to serve in invasion and infection (Inoshima, 2011). Other 
proposed regulators of E-cadherin that may aide in barrier breakdown include PAK1 which is 
thought to be activated by Rac1 (Menke, 2012). Rac1also works to activate the p38 cascade, 
which is indicated in the literature to lead to membrane degradation and subsequently S. 
pneumoniae translocation (Clarke, 2011; Beisswenger, 2007; Menke, 2012).  
 The actin cytoskeleton is associated with tight junctions through the interaction of β-
catenin, E-cadherin and α-catenin, another member of the catenin family, (Menke, 2012). 
TGF-β1 signalling may be located upstream of the Rho GTPase RhoA which acts on the actin 
cytoskeleton causing cellular morphological changes and leading to the reorganization of F-
actin (Shao, 2011).  
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 Rho GTPases act via various signalling pathways to aid in the maintenance of cellular 
integrity by associating cell junction formation and maintenance with actin cytoskeletal 
rearrangements. Rho GTPases are key mediators of actin cytoskeleton organization, adherens 
junction formation and epithelial morphology. The main Rho GTPases involved in the cell 
junction and cytoskeletal processes are Cdc42, Rac1 and RhoA (Menke, 2012; Shao, 2011). 
These GTPases have been shown to regulate actin remodelling processes such as membrane 
ruffling and stress fibre formation that are known to play a role in host invasion by leading to 
the uptake of bacteria like Listeria monocytogenes and S. pneumoniae (Menke, 2012; Braun, 
1999;Yamaguchi, 2013). Cdc42 is involved with the cytoskeleton and is known to interact 
with E-cadherin to induce a polarized phenotype in epithelial cells (Desai, 2009). This 
GTPase also works to control junction integrity by regulating the interaction of junction 
molecules with the actin cytoskeleton. Activation of Cdc42 leads to the recruitment of E-
cadherin and filamentous actin to cell to cell junctions. When E-cadherin arrives at these 
junctions it forms new contacts and this leads to junction formation. The formation of new 
junctions activates Rac1 leading to an increase in the formation of E-cadherin contacts and 
resulting in stronger cell-cell junctions (Menke, 2012). Cell junction integrity is further 
strengthened through actin polymerization which is initiated thru signalling pathways 
triggered by the interaction of Rac1 with PAK kinases (Zhao, 1998). The Rho GTPases, 
Cdc42 and Rac1 have been shown to link E-cadherin ligation to cell survival via Stat3 
pathways resulting in an anti-apoptotic signal (Arulanandam, 2009).  
1.3.1 Pneumolysin and Tight Junction Integrity 
PLY is considered one of the main virulence factors of S. pneumoniae and is 
expressed in almost all clinical isolates. This fact has led to it being implicated as a major 
player in the progression of S. pneumoniae from a harmless commensal to a pathogen causing 
invasive disease. The exact role of PLY in invasion is hard to determine as varying 
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concentrations of this toxin encounter many types of host cells and environments making 
isolating the exact pathways and signalling cascades triggered by PLY difficult. It is likely 
that PLY triggers multiple signalling cascades that work in tandem to allow for the invasion 
of this bacterium in a host environment.  Inoshima et al. (2011) found some PLY 
concentrations led to E-cadherin cleavage in A549 cells. However, it was suggested that the 
cleavage have been triggered by apoptotic pathways rather than the ADAM10 mechanism, 
which is involved in E-cadherin cleavage when cells were exposed to α-hemolysin, as the E-
cadherin was shown to be cleaved only when the A549 cells were exposed to lytic 
concentrations of PLY (Inoshima, 2011). The serine threonine specific protein kinase PKC-α 
has roles in the epithelium and may also aid in the invasion of S. pneumoniae. Increased PKC-
α activity has been shown to lead to the decreased ability of tight junctions to form proper 
barriers. This kinase has an unusual mode of regulation that is controlled by the plasma 
membrane. The activity levels of this kinase are influenced by plasma membrane 
characteristics such as the length of the hydrophobic domain and the fluidity of the lipid 
bilayer. Low concentrations of diacylglycerols and the ions calcium and magnesium cause 
increased fluidity and short hydrophobic domains within the plasma membrane leading to an 
increase in PKC-α activity (Micol, 1999). Lucas et al (2012) showed that sublytic 
concentrations of PLY led to activation of PKC-α within 30 minutes of exposure (Lucas, 
2012). It may be that the activation is due to the insertion of PLY monomers in the lipid 
bilayer causing a disturbance in fluidity.  PKC-α activation could also be the result of 
changing calcium concentrations within the cell as PLY pores are large and allow calcium 
ions to flood into a cell but as pores are also rapidly repaired it is not a steady influx. 
Capillary leakage by PLY exposure was found to be decreased when the PKC-α inhibitor 
Ro32-0432 is applied. The alveolar epithelial barrier was found to be significantly inhibited in 
vivo with PKC-α activity (Lucas, 2012). TLR4 may also have roles in tight junction integrity 
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as a study by Wardill et al (2013) describes how TLR4 leads to a change in tight junction 
integrity through the initiation of PKC activity in gut epithelial cells (Wardill, 2013). PKCs 
may be involved with the breakdown of tight junctions in other types of epithelial cells 
leading to S. pneumoniae invasion into the bloodstream.  
Another hypothesis for PLY role in invasion centres around its effects on the actin 
cytoskeleton and intercellular junctions. Effects on these systems have been investigated in 
neuronal cells and endothelial cells. The activation of two small GTPases, Rac1 and RhoA, 
occurred when astrocytes were exposed to sublytic concentrations of PLY, (Hupp, 2012). 
Both Rac1 and RhoA have been linked to regulation of the actin cytoskeleton through cell 
movement or the formation of stress fibres respectively. Rac1 aids in the formation of 
lamellipodia and may utilize calcium in its activation as the activation of Rac1 by PLY is 
inhibited when calcium free buffer is used. RhoA aids in the formation of stress fibres, an 
effect that seems to be regulated through the usual RhoA to Rho associated protein kinase 
(ROCK) pathway. Evidence of this is found when treatment with a ROCK inhibitor negates 
the increase in stress fibres found in an uninhibited system. Unlike Rac1, RhoA does not seem 
as dependent on calcium as its induction was similar regardless of the concentration or 
presence of calcium in the buffer (Iliev, 2007). How these GTPases aid in invasion is seen 
when the effects Rac1 and RhoA have on cell barriers comes into play. Rac1 has been shown 
to be cell barrier protective while RhoA has been shown to be cell barrier disruptive. When 
cells are exposed to PLY an imbalance of these two proteins occurs. The negative effects of 
the GTPase imbalance have been shown to be reduced when cells are treated with an inhibitor 
of PKC-α, TIP peptide, which mimics the lectin like domain of TNF-α (Lucas, 2012). A study 
of the blood brain barrier implicated the RhoA/ROCK pathway as having an effect on the 
GTPase imbalance and subsequently disrupting the protective nature of cell barriers. This 
study found that the RhoA/ROCK pathway triggered phosphorylation of myosin light chain 
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which also occurs when cells are treated with PLY (Srivastava, 2013; Lucas, 2012). 
Srivastava et al also found that the myosin light chain phosphorylation led to the breakdown 
of occludin which is one of the main components of tight junctions (Srivastava, 2013). This 
brings the question of whether PLY-induced activation of the RhoA GTPase pathway also 
leads to the disruption of occludin which could result in the invasion of pneumococci from the 
nasopharynx to the blood or CSF due the dysfunctional tight junctions. Evidence for a direct 
relationship between PLY and VE-cadherin was found when lung endothelial cells were 
treated with sublytic concentrations of PLY. PLY treatment for 2 hours led to a significant 
decrease in VE-cadherin resulting in an increase in gap formation. The monolayer integrity 
was rescued when TIP peptide was applied. This evidence again links TNF-α and RhoA/Rac1 
to the story of cell barrier dysfunction (Lucas, 2012). PKC-α has also been linked with 
RhoA/Rac1 and may prove to be an upstream member of this pathway providing a bridge 
between extracellular PLY and intracellular signalling (Lucas, 2012). 
Pneumolysin, the pore forming toxin of Streptococcus pneumoniae, and a member of 
the CDC protein family is an important factor in causing invasive disease in human hosts. 
This protein has been linked to many signalling cascades that are associated with the 
formation and integrity of epithelial cell barriers but has not been directly linked to the 
cleavage of E-cadherin or another epithelial cell protein that would allow the passage of 
Streptococcus pneumoniae into the host. One of the aims of this project was to look into these 
pathways and see if there is any connection between PLY and a disruption of the epithelial 
cell barriers. 
1.4 Aims and Objectives 
The aim of this Masters project was to investigate the various effects of pneumolysin 
on host cells and to try to identify host-pathogen interactions that could contribute to the 
switch from harmless commensal to invasive disease with the main focus on epithelial cell 
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barriers. The toxin was tested on lung epithelial cells to assess the damage caused under 
various concentrations of toxin.  
A specific objective was to determine if the toxin pneumolysin has any effect on 
adherence of the bacterium to its host as pneumolysin is present in almost every case of 
clinical disease caused by S. pneumoniae. This led to investigating the degradation of E-
cadherin when lung epithelial cells were exposed to the pneumolysin toxin. The Inoshima 
group (2011) investigated the zinc metalloproteinase ADAM10 pathway and discovered that 
it led to degradation of E-cadherin when A549 lung epithelial cells were exposed to another 
pore forming toxin, α-hemolysin. The observation by this group led to one of the key 
questions in this project, is E-cadherin degraded by the ADAM10 pathway when A549 cells 
are exposed to pneumolysin as it is when they are exposed to α-hemolysin? There is already 
evidence of some activation of the ADAM10 pathway with pneumolysin. But as pneumolysin 
is a large pore forming protein whereas α-hemolysin is a small pore forming protein, the 
question remains of whether an influx of calcium ions trigger the normal cellular apoptotic 
pathways leading to the degradation of E-cadherin is the mechanism followed in S. 
pneumoniae-host interactions. This apoptosis driven alternative hypothesis is supported by 
evidence of E-cadherin degradation when pneumolysin is present in lytic but not sublytic 
concentrations. 
Another question raised by previous studies was whether the morphological changes 
to the cytoskeleton that occur in the host when exposed to pneumolysin were cause by a direct 
interaction between the toxin and actin or whether the toxin instead triggers Rho GTPase 
signalling pathways within the host which lead to the observed morphological changes in the 
cytoskeleton. These cytoskeletal changes could be another pathway which aid in streptococcal 
invasion in the host. This line of investigation was inspired by the work of the Iliev group 
(Iliev, 2007; Hupp, 2012).  
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Other preliminary objectives of this project included investigating the localisation of 
pneumolysin by producing a fluorescent tagged, endogenously produced toxin and producing 
a chemically defined media which could be used in studies that focus on the host cell repair 
mechanisms. The ability to remove ions such as calcium would highlight the importance of 
these ions and the pathways in which they are involved in the cell choice between repair and 
apoptosis. 
 In summary, this study was interested in purifying wild type pneumolysin and a 
nonhaemolytic toxoid in order to determine if invasion of the host by S. pneumoniae is 
enhanced by the pore forming toxin pneumolysin and whether or not pneumolysin plays a key 
role in adherence of S. pneumonaie to the host.   
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 Chapter 2: Methods and Materials 
2.1 Protein Purification 
2.1.1 Purification of pneumolysin  
 E. coli containing pET-33BPLY plasmid for expression of His-tagged pneumolysin 
were grown overnight in LB broth (Sigma) + 50μg/ml kanamycin (Sigma). Four flasks of 1L 
of LB broth + 50μg/ml kanamycin each were then inoculated with 10ml of overnight culture 
each. E. coli was allowed to grow at 37
o
C whilst shaking until OD600 0.8 was reached. A 
concentration of 1mM IPTG (Fisher) was then added to each flask. Cultures were allowed to 
grow for another 3 hours before cells were collected by centrifugation at 3220 x g for 25 
minutes at 4
o
C and the pellet resuspended in 5ml of PBS per litre of culture. The pellet was 
frozen at -20
o
C with protease inhibitors (Roche), DNase 1 (Sigma), and benzamidine (Sigma) 
to prevent any degradation. The pellet was then thawed on ice before disrupting the cells 
using the one shot cell disrupter set to 12k PSI. The disrupted cells were then centrifuged at 
18000 x g for 40 minutes at 4
o
C to remove debris. The lysate (supernatant) was then run 
through a 5ml nickel affinity column to load the protein. Nickel Affinity Chromatography by 
imidazole (Acros Organics) gradient was then performed using the Akta Primeplus (GE). 
Fractions were run on SDS-PAGE and stained with Coomassie blue to determine fractions to 
be pooled and dialysed using dialysis tubing in 2L of Anion Exchange wash buffer for at least 
24 hours. Dialysed protein was loaded by recirculation through an Anion Exchange column 
for at least 20 minutes on ice on loop to load the column. Protein then underwent Anion 
Exchange Chromatography by NaCl (Merck) gradient using the Akta Primeplus. Fractions 
were again run on SDS-PAGE and stained with Coomassie blue to determine fractions to be 
pooled. Dialysis was performed in 2L of 1x sterile PBS pH 7.4 for at least 24 hours before 
being changed to 2L of fresh 1x sterile PBS and left for another 24 hours. Protein was then 
collected and the concentration measured on the ND-1000 Nanodrop. Protein was diluted to 
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as close to 1.0 mg/ml as possible by very slowly adding 1x sterile PBS before aliquoting and 
freezing down into the -20
o
C and -80
o
C freezers for future use. 
2.1.2 Protein purification of Δ6PLY and eGFPΔ6PLY 
 Δ6PLY is a pneumolysin mutant that was created by an amino acid deletion of the 
amino acids alanine 146 and arginine 147 leading to a nonhaemolytic version of the toxin. 
The monomers of Δ6PLY attach to the membrane but the protein cannot complete the 
conformational change required to insert into the host membrane. 
E. coli containing pET-33BΔ6PLY plasmid (Kirkham 2006) for expression of his-
tagged Δ6PLY protein or E. coli containing pET-33BeGFPΔ6PLY (Cowan 2006) plasmid for 
expression of his-tagged, eGFP fluorescence conjugated Δ6PLY protein were grown 
overnight in LB broth (Sigma) + 50μg/ml kanamycin (Sigma). Four flasks of 1L of LB broth 
+ 50μg/ml kanamycin each were then inoculated with 10ml of overnight culture each. E. coli 
was allowed to grow at 37
o
C whilst shaking until OD600 0.8 was reached. A concentration of 
1mM IPTG (Fisher) was then added to each flask. Cultures were allowed to grow for another 
3 hours before cells were collected by centrifugation at 3220 x g for 25 minutes at 4
o
C and the 
pellet resuspended in 5ml of PBS per litre of culture. 
Purification proceeded as per section 3.1.1 above. 
2.1.3 Generation of Negative Vehicle for Purified Pneumolysin 
 A negative control, termed vehicle, was made from the solvent fraction of the PLY 
preparation without the toxin. To generate a negative vehicle, pneumolysin was absorbed 
from the buffer using affinity chromatography. 200μl of nickel magnetic beads (Millipore) to 
bind to the His tag of the PLY toxin were added to a 1.5ml microcentrifuge tube and placed in 
a magnetic rack. The storage solution was removed and the beads washed in 200μl of DPBS, 
after which 200μl of purified WTPLY NC-01 was added to the beads. The toxin and beads 
were mixed by pipetting and the 1.5ml microcentrifuge tube was placed on a shaker for 1 hour 
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at room temperature. To retrieve the negative vehicle, the 1.5ml microcentrifuge tube was 
placed back on the magnetic rack and the supernatant transferred to a new 1.5ml 
microcentrifuge tube. 
2.1.4 Generation of Nickel Elution Protein for Purified Pneumolysin 
 To generate the nickel eluted protein, 200μl of nickel elution buffer, buffer containing 
imidazole used to elute the protein of interest from the nickel chromatography column was 
added to the nickel magnetic beads after the negative vehicle was removed. The beads and 
buffer solution was mixed by pipetting in a 1.5ml microcentrifuge tube and placed on an 
orbital shaker (Orbital Shaker S03 Stuart Scientific) for 1 hour at room temperature. To 
retrieve the nickel eluted protein, the 1.5ml microcentrifuge tube was placed back on the 
magnetic rack and the supernatant transferred to a new 1.5ml microcentrifuge tube. 
2.2 Cell Based Assays 
2.2.1 Haemolytic assay 
 In duplicate, 50μl of a positive control (lab stock pneumolysin, 1μg/ml), the newly 
purified pneumolysin (batch NC-01, 1μg/ml) and negative vector (magnetic Ni bead flow 
through, neat) were serially diluted in 50μl of DPBS (Sigma) across the rows of a 96 well 
round bottom plate (Sarstedt) To each well, 50μl of 10Mm DTT (Melford) diluted in DPBS 
was added. The 96 well plate was covered and allowed to incubate at 37
o
C for 15-30 minutes. 
During incubation, 1ml of sheep blood (E&O Laboratories) was centrifuged to collect 
erythrocytes in a pellet discarding the supernatant. Cells were washed until the supernatant 
was clear. The cleaned erythrocytes were diluted into a 2% solution in DPBS. After the 
incubation time, 50μl of 2% erythrocyte solution was added to each well and the plate was 
covered and allowed to incubate at 37
oC for 30 minutes. After the incubation, 50μl of DPBS 
was added and the plate was centrifuged for 1 minute at 138 x g (Eppendorf) to collect the 
remaining erythrocytes in pellets at the bottom of each round well. After spinning, 100μl of 
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supernatant was transferred from each well to a new flat bottom 96 well plate (Falcon) and 
absorbance 540nm was measured in a plate reader (BMG Labtech Omega Fluorostar) to 
analyse lysis. 
2.2.2 Lactate Dehydrogenase (LDH) Assay 
 The results of the LDH assay indicate membrane permeability as LDH is small 
enough to escape through the large pore formed by PLY. L929 fibroblast cells were seeded 
into a 96 well plate (Falcon) at a concentration of 6 x 10
4
 cells/well. After overnight 
incubation to allow cells to attach, all supernatant was removed from the wells and replaced 
with media (RPMI 1640 (Sigma), 10% FCS (Labtech), 1% L-glutamine (Sigma), 1% 
penicillin/streptomycin (PAA)) containing the appropriate concentrations of WTPLY NC-01 
(10μg/ml, 0.5μg/ml, 0.1μg/ml, and 0.05μg/ml diluted in RPMI media), negative vehicle (same 
volume added as the WTPLY concentrations), or media alone in triplicate. Cells were 
incubated for 37
o
C and 5% CO2 in conditions for 3 or 6 hours before the supernatant was 
removed for the assay. Supernatant processing, lysis control, and positive control were done 
following the manufacturer’s instructions. LDH assay kit used was Promega Cytotox 96 Non-
Radioactive Cytotoxicity Assay.  
2.2.3 MTT (3-(4, 5-Dimethylthiazol-2yl)-2, 5-diphenyltetrazolium bromide) Assay 
 The results of the MTT assay indicate live or dead cells. L929 fibroblast cells were 
seeded into a 96 well plate (Falcon) at a concentration of 6 x 10
4
 cells/well. After overnight 
incubation to allow cells to attach, all supernatant was removed from the wells and replaced 
with media (RPMI 1640, 10% FCS, 1% L-glutamine, 1% penicillin/streptomycin; Sigma) 
containing the appropriate concentrations of WTPLY NC-01 (10μg/ml, 0.5μg/ml, 0.1μg/ml, 
and 0.05μg/ml in RPMI), negative vehicle (same volume added as the WTPLY 
concentrations), or media alone in triplicate. Cells were incubated for 37
o
C and 5% CO2 in 
conditions for 3 or 6 hours before the supernatant was removed. After exposure time, 50μl of 
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MTT stain (Thiazolyl Blue Tetrazolium Bromide (Sigma) diluted in Dulbecco’s PBS 
(Sigma)) was added to each well. Cells were incubated at 37
o
C, 5% CO2 for a further 4 hours. 
After incubation all liquid was removed and 100μl of MTT solvent (40μl HCl n 10ml 
isopropanol) was added to each well. Liquid was mixed using an orbital shaker for 2 minutes 
at 150 RPM. Absorbance was read in a plate reader at a wavelength of 540nm.  
2.3 Host-pathogen interactions 
2.3.1 Growth curves 
 Standard inocula were used for growth curves so that the CFU/ml and OD600 of the 
bacteria were constant. Strains used were WT D39 and WT TIGR4 Streptococcus 
pneumoniae lines (see Appendix II: Strains used in this study for further details). Standard 
inocula were retrieved from the -80 freezer and quick thawed in a 37
o
C water bath. They were 
transferred to a 1.5ml microcentrifuge tube and centrifuged at 3200 x g for 5 minutes. Pellets 
were washed twice in 1x sterile PBS before use. Both strains at OD600 0.3 were added to a 96 
well flat bottom plate (Falcon) at 0.15 CFU/ml in triplicate in both BHI (Oxiod) and CDM 
media. Media alone served as negative controls and blanks. The 96 well plate was covered 
and allowed to incubate in the plate reader for 18 hours under normal atmospheric conditions 
reading every 30 minutes. During the plate reader experiment, duplicate cultures of 10ml of 
BHI or CDM and 0.15 CFU/ml of each bacterial strain per condition were allowed to grow 
under atmospheric conditions in a 37
o
C water bath. Every hour for the first 4 hours of growth 
a 1ml sample from each strain in each condition was taken and OD600 measured. Samples 
were centrifuged for 5 minutes at 3200 x g. Pellet was washed twice and resuspended in 
sterile PBS. Viable counting was done in duplicate with triplicate spots for each sample to 
more accurately determine growth in CFUs/ml.  
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2.3.2 Transformation of E. coli  
 A 100µl aliquot of XL1-Blue competent E. coli was taken from the -80
o
C freezer for 
each condition. The aliquot was allowed to thaw on ice before 1ml of plasmid DNA pJWV25 
was added and incubated for 20 minutes on ice before being transferred to a chilled 0.1cm 
electroporation cuvette (Cell Projects). Electroporation was accomplished using the following 
settings: 2.5Kv, 25mF, and 200Ω (GenePulsar Electroporator).  The cuvette was returned to 
ice and 200ml of room temperature SOC media was added. Samples were then transferred to 
a microcentrifuge tube and incubated for 1 hour at 37
o
C. Various volumes of sample were 
plated on LB agar + 100μg/ml of ampicillin (Sigma). Plates were incubated overnight at 37oC 
and checked for colonies the following day. 
2.3.3 Plasmid DNA preparation 
 Plasmid DNA was prepared using 5ml of overnight culture of E. coli in LB broth + 
ampicillin (Sigma) for pJWV25 plasmid and the Qiagen Spin Miniprep Kit (QIAGEN). The 
manufacturer’s instructions were followed choosing the optional step and elution in 30ml of 
molecular grade dH20 (Sigma).  
2.3.4 Transformation of S. pneumoniae 
 S. pneumoniae D39 was grown on a blood agar plate (BAB No. 2 (Oxoid) + 5% Horse 
blood (E&O Laboratories)) overnight at 37
o
C and 5% CO2. The following day, 10ml of sterile 
BHI (Oxoid) was inoculated with a loopful of D39 from the blood agar plate and allowed to 
grow overnight at 37
o
C and 5% CO2. The next day, 30ml of sterile BHI + 1mM CaCl2 (BDH) 
was inoculated with 500μl of overnight culture and incubated until an OD600 of 0.1 to 0.3 was 
reached. For each transformation, 1ml of culture and 100ng/ml CSP-1 were added into a 
1.5ml microcentrifuge tube. Cultures were incubated in a 37
o
C water bath for 15 minutes. The 
plasmid of interest or a control plasmid with the desired antibiotic resistance was added to 
each respective culture and cultures were incubated for a further 1 hour 15 minutes in a 37
o
C 
water bath. A 300μl aliquot of each culture was spread onto respective BAB plates and 
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allowed to incubate at 37
o
C and 5% CO2 overnight. Any colonies were picked and replated 
onto antibiotic plates to test for selection. 
2.3.5 Extraction of genomic DNA from bacteria  
 Genomic DNA was extracted using the (Nexttec). Solutions were made fresh per 
sample are as shown in the table below and were mixed by pipetting before use: 
Solution Name Nexttec Reagent Name Amounts of Reagents 
Lysis Buffer 1 (LB1 ) 
Buffer B1 90μl 
Lysozyme 10μl 
RNase A 20μl 
Lysis Buffer 2 (LB2) 
Buffer B2 2.5μl 
Buffer B3 10μl 
Purified Dh20 87.5μl 
DTT 2.5μl 
EDTA 2.0μl 
Per sample, 120μl of LB1 were added to a screw cap tube. A generous loopful of bacteria was 
added to the screw cap tube and mixed with pipetting. To give continuous agitation, samples 
were incubated in a hybridisation chamber at 60
o
C for 20 minutes. After initial incubation, 
104μl of LB2 was added to each tube and mixed by pipetting. Samples were allowed to 
incubate in the hybridisation chamber for 60 minutes at 60
o
C. Columns were prepared by 
adding 350μl Prep Buffer (Nexttec) to the column and leaving at room temperature for at least 
5 minutes. Columns were then centrifuged at 350g for 1 minute. Flow through was discarded 
and a new microcentrifuge tube was connected to the column. After the hour incubation, the 
entire sample was pipetted onto the column and left to incubate at room temperature for 3 
minutes. The column was centrifuged at 700g for 2 minutes then flow through was collected 
into a new tube and the concentration measured via Qubit fluorometer (Invitrogen). DNA was 
stored at -20
o
C until required. 
2.4 Exposure of A549 Lung Epithelial Cells to GFP tagged toxin  
2.4.1 Exposure of A549 Lung Epithelial Cells to eGFP tagged PLY toxin 
 A549 human lung carcinoma epithelial cells were seeded at a density of 7500 
cells/well onto a 10mm, size 0, uncoated, sterile coverslip within a 24 well plate (Costar). 
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Complete Dulbecco’s Modified Eagle Medium (DMEM) [see Appendix 1] was added to each 
well and cells were allowed to incubate at 37
o
C, 5% CO2 for 48 hours or until a monolayer 
formed. After the appropriate incubation time, the media was removed from the well. An 
eGFP fluorescently tagged version of PLY (eGFPPLY) was added to the monolayers at the 
following concentrations: 1.1µM, 11.1µM and 111.2µM. The cells and toxin were allowed to 
incubate for 30 minutes at 37
o
C and 5% CO2. After the incubation time the media and toxin 
was removed and the monolayers were washed in 1ml of warm complete DMEM. Cells were 
fixed with 3.8% paraformaldehyde (PFA; Affymetrix) in media for 10 minutes at room 
temperature. After fixation the PFA solution was removed and monolayers were washed 3 
times with 1 ml of DPBS each time. Coverslips were then mounted to slides using 2ul of 
Prolong Gold Antifade Reagent with DAPI (Life Technologies) and sealed with nail varnish. 
After allowing 24 hours for the slides to dry, coverslips were visualized using confocal 
microscopy (Nikon A1 Confocal Microscope). 
2.4.2 Exposure of A549 Lung Epithelial Cells to eGFP tagged Δ6PLY toxin with Live 
Cell Imaging 
A549 lung epithelial cells were seeded at a density of 2x10
5
 cells/well into a 24 well plate 
(Costar). Complete Dulbecco’s Modified Eagle Medium (DMEM) [see Appendix 1] was 
added to each well and cells were allowed to incubate at 37
o
C, 5% CO2 for 48 hours or until a 
monolayer formed. After the appropriate incubation time, the media was removed from the 
well. An eGFP fluorescently tagged version of Δ6PLY (Δ6eGFPPLY) was added to the 
monolayers at the following concentrations: 1.8µM, 18.1µM and 180.6µM to match the wild 
type concentrations. The cells and toxin were allowed to incubate for 30 minutes at 37
o
C and 
5% CO2. After the incubation time the media and toxin was removed and the monolayers 
were washed in 1ml of warm DPBS. RPMI medium without phenol red (Sigma) 
supplemented with 1mM sodium pyruvate (Sigma) and 10% FCS (Gibco) was added at a 
Culverhouse 22 
 
volume of 1ml to each well and cells were then visualized using confocal microscopy (Nikon 
A1 Confocal Microscope). 
2.5 Immunofluorescence Microscopy 
2.5.1 Toxin exposure following by staining for cellular actin  
In a 24 well plate (Costar), A549 lung epithelial cells were seeded at a density of 7500 
cells/well onto an uncoated 10mm diameter, 0 thickness coverslip. Cells were allowed to 
grow for approximately 48 hours in complete DMEM media [see Appendix 1] at 37
o
C and 
5% CO2 until a monolayer was formed. After a monolayer was formed on the coverslip, the 
media was removed from the well and eGFPPLY toxin diluted in warm, complete DMEM 
media was added at varying concentrations to the appropriate wells. Cells were incubated for 
2 minutes at 37
o
C and 5% CO2. The toxin and media were removed from each well and the 
cells were washed in 1ml warm complete DMEM media. Cells were then fixed by adding 1ml 
of 3.8% paraformaldehyde (4% PFA; Affymetrix) in complete DMEM media and allowed to 
incubate at room temperature for 10 minutes. The fixative solution was then removed and the 
coverslip was washed 3 times with 1ml of warm DPBS (Sigma). Cells were then 
permeablilized by adding 1ml of 0.1% Triton X-100 (Sigma) diluted in DPBS to the 
necessary wells and incubated at room temperature for 5 minutes. The next step required the 
coverslips be washed in 1ml of warm DPBS 3 times. A blocking step was then performed by 
adding 1ml of 4% BSA (Sigma) diluted in warm DPBS to the coverslips and allowing them to 
incubate at room temperature for 30 minutes. The coverslips were again washed 3 times in 
1ml of warm DPBS before incubating with Phalloidin Alexa Fluor 555 (Life Technologies) 
diluted 1 in 200 in warm DPBS to stain for F-actin. A final incubation in the phalloidin 
antibody was performed for 20 minutes at room temperature before the coverslips were 
washed 3 times with 1ml of warm DPBS. Coverslips were then touched to a paper towel to 
remove excess DPBS before being mounted onto a slide with 2μL of Prolong Gold Antifade 
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Reagent with DAPI (Life Technologies) and sealed with nail varnish. Slides were allowed 
overnight to dry and ensure mount was hardened before visualizing by confocal microscopy 
(Nikon A1 Confocal Microscope). 
2.5.2 E-cadherin staining 
In a 24 well plate (Costar), A549 lung epithelial cells were seeded at a density of 7500 
cells/well onto an uncoated 10mm diameter, 0 thickness coverslip. Cells were allowed to 
grow for approximately 48 hours in complete DMEM media [see Appendix 1] at 37
o
C and 
5% CO2
 
until a monolayer was formed. After a monolayer was formed on the coverslip, the 
media was removed from the well and the cells were washed 3 times in 1ml warm DPBS 
(Sigma). Cells were then fixed by adding 1ml of 3.8% paraformaldehyde (PFA; Affymetrix) 
in complete DMEM media and allowed to incubate at room temperature for 10 minutes. The 
fixative solution was then removed and the coverslip was washed 3 times with 1ml of warm 
DPBS. Cells were then permeablilized by adding 1ml of 0.1% Triton X-100 (Sigma) diluted 
in DPBS to the necessary wells and incubated at room temperature for 5 minutes. Coverslips 
were then washed 3 times in 1ml of warm DPBS. Coverslips were then blocked by adding 
1ml of 4% BSA (Sigma) diluted in warm DPBS and allowed to incubate at room temperature 
for 30 minutes. The coverslips were again washed 3 times in 1ml of warm DPBS before 
incubating with mouse monoclonal E-cadherin primary antibody (Biolegend) at a 
concentration of 1 in 50 diluted in warm DPBS. The coverslips were allowed to incubate in 
the primary antibody for 1 hour at room temperature before being washed 3 times with 1ml of 
warm DPBS. Alexa Fluor 633 anti-mouse secondary antibody (Life Technologies) was then 
added to the coverslips at a concentration of 1 in 1000 diluted in warm DPBS. Cells were 
allowed to incubate in the secondary antibody for 1 hour at room temperature before being 
washed 3 times in 1ml of warm DPBS. Coverslips were then touched to a paper towel to 
remove excess DPBS before being mounted onto a slide with 2μL of Prolong Gold Antifade 
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Reagent with DAPI (Life Technologies) and sealed with nail varnish. Slides were allowed 
overnight to dry and ensure mount was hardened before visualizing by confocal microscopy 
(Nikon A1 Confocal Microscope). 
2.6 Western blotting for E-cadherin 
 A549 cells were grown to confluent monolayers in a 75cm
2
 tissue culture flask 
(Starstedt). The media was removed and the monolayers were washed once in DPBS (Sigma). 
Where applicable, wild type pneumolysin was added in the appropriate concentrations in 
serum-free media. Cells were allowed to incubate for 1 hour at 37
o
C and 5% CO2. After the 
incubation, monolayers were washed once in DPBS and lysis buffer [see Appendix 1] was 
then applied to each monolayer in an appropriate amount (1ml for 75cm
2
 tissue culture flask). 
Cells were visually checked for lysis using a microscope, ensuring cells had rounded and 
shrunk down. Once lysis occurred, the lysis buffer combined with cell material was collected 
and centrifuged at 21728 x g on a benchtop centrifuge (Eppendorf) for 10 minutes to remove 
cellular debris. After centrifugation, the supernatant was collected and used for SDS-PAGE. 
For each sample, 9μl of supernatant was added to 3μl of SDS PAGE sample buffer (4x 
reducing SDS PAGE sample buffer [see Appendix 1]) and heated for 10 minutes at 70
o
C. 
Samples were loaded onto a bis-tris gel (NuPAGE 4-12% Bis-Tris Gel, Novex Life 
Technologies) and ran for 50 minutes at 180 volts. Protein was then transferred to a 
nitrocellulose membrane for Western blotting (iBlot Gel Transfer Mini Stack, Novex Life 
Technologies).  
 For Odyssey visualisation, the membrane was blocked in 3% BSA (Sigma) in TBST 
[see Appendix 1] for 1 hour at room temperature before primary E-cadherin mouse 
monoclonal antibody (Biolegend) and anti-actin rabbit polyclonal antibody made to 1in 500 
dilution in 3% BSA + TBST and added to the membrane.  Membrane was incubated in 
primary antibody for 16 hours at 4
o
C. After incubation, the membrane was washed 3 times 10 
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minutes in high salt TBST [see Appendix 1]. The membrane was then incubated in anti-
mouse conjugated 800 and anti-rabbit conjugated 700 secondary antibodies (IRDye secondary 
antibodies; Licor) at 1:10000 for 1 hour shaking at room temperature. After incubation in 
secondary, the membrane was washed 5 times 5 minutes in high salt TBST followed by a 
further 2 washes in TBS [see Appendix 1]. Membrane was dried using Whatman paper and 
visualised in both the 700nm and 800nm channels of the Licor Odyssey Infrared Imager 
(Licor). 
2.7 Adherence Assay 
 A549 lung epithelial cells were seeded into a 24 well plate (Costar) at a density of 
2x10
5
 cells into 1ml of RPMI medium without phenol red (Sigma) supplemented with 1mM 
sodium pyruvate (Sigma) and 10% FCS (Gibco). Cells were placed in the incubator at 37
o
C 
and 5% CO2 overnight to allow for attachment. After overnight incubation, the media was 
removed from the cells and replaced with fresh media. After a further 24 hour incubation, 48 
hours in total, cells were confluent. The media was removed from the wells and the 
monolayer was washed two times with 2ml of sterile DPBS (Sigma) each time.  
Starter cultures of strains of S.pneumoniae (FP22, D39, D39 PLY STOP, and R6 see 
Appendix II: Strains used in this study for further details).at an OD600 of 0.6, mid log, were 
warmed briefly in the water bath before centrifuging at 3200 x g for 5 minutes and washing in 
1ml sterile DPBS. This process was repeated for a total of 2 times. The 1ml of bacterial 
culture was then re-suspended after a final centrifugation into RPMI without phenol red 
supplemented with 1% FCS. Bacteria were added to each corresponding monolayer at 1x10
7
 
CFU/ml per well. The CFU/ml was predetermined by viable counting and was confirmed via 
a viable count of the starting inoculums for each type of bacteria used. The cells and the 
bacteria were then incubated for 2 hours at 37
o
C and 5% CO2. After the incubation time, the 
medium was removed from each well and the monolayer of cells was washed 3 times with 
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1ml of sterile DPBS. The monolayer was then washed with 200μl of 1x trypsin/EDTA 
(Sigma) for approximately 10 minutes at 37
oC until cells freely detached from the plate. 800μl 
of ice cold, sterile dH2O was added to lyse the A549 cells releasing the adhered bacteria. The 
resulting A549 lysate suspension was serial diluted and viable counted. The percent adherence 
was then calculated using the viable count from the starting inoculums and the final viable 
count. 
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Chapter 3: Results 
3.1 Protein purification 
3.1.1 Purification of the pore forming protein pneumolysin 
The first step to testing the effects of pneumolysin on various host cell pathways was 
to purify and quality check recombinant pneumolysin. To produce large quantities, BL21 E. 
coli expressing the plasmid pET33BPLY, which is the pET33b plasmid with the addition of 
the PLY gene linked to a His tag were grown and PLY purified as described in section 2.1.1. 
The His tag was included in this protein to allow for purification via nickel affinity 
chromatography. The protein was then subjected to anion exchange chromatography to 
separate the protein of interest from any contaminants such as lipopolysaccharide (LPS) that 
can occur from producing this protein in E. coli rather than its native bacterium S. 
pneumoniae. If LPS remains in the protein preparation the results of cell based assays would 
be inconclusive as there would be no way to determine if the effect was due to PLY or LPS.  
Quality control steps were performed after each stage of purification. Fractions were 
selected from the peak of the AKTA trace profiles and analysed by gel electrophoresis and 
western blotting to ensure only the purest and highest concentration protein fractions would 
be carried to the next step of protein purification (Figure 3.1 for NAC and 3.2 for AEC).  
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Figure 3.1 Results of pnuemolysin purification after Nickel Affinity Chromatography A: 
AKTA profile showing the protein in each 1ml fraction eluted from the NAC column B: 
Coomassie gel depicting fractions 12-20 diluted 1:10 selected from peak on AKTA trace C: 
Western blot depicting fractions 12-20 diluted 1:10 selected from peak on AKTA trace. Red 
arrows on Coomassie gel and western blot point to protein of interest, WTPLY at expected 
molecular weight of 57kDa. 
The NAC fractions 18 to 20 were combined for dialysis before continuation to AEC. 
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Figure 3.2 Results of pneumolysin purification after Anion Exchange Chromatography 
A: AKTA profile showing the protein in each 1ml fraction eluted from the AEC column B: 
Coomassie gel depicting chosen fractions 11-19 selected from peak on AKTA trace C: 
Western blot depicting chosen fractions 11-19 selected from peak on AKTA trace. Red 
arrows on Coomassie gel and western blot point to protein of interest, WTPLY at expected 
molecular weight of 57kDa. 
The AEC fractions 12 thru 14 were combined for dialysis and ultimately became the 
final WTPLY protein. The concentration of the PLY produced was 1.81mg/ml and was given 
a batch coding of NC-01. A Coomassie gel and western blot were performed in order to 
ensure the protein purified was pneumolysin and that no contaminants were present (Figure 
3.3). The Coomassie gel was used to check for any large contaminants that may have eluded 
the purification process as Coomassie stains all protein non-specifically. The Coomassie gel 
run in this case shows a single band for WTPLY NC-01 at a size of 57 kDa. This is the 
expected size for the recombinant His-tagged pneumolysin. The western blot shows 2 bands, 
the expected pneumolysin band and a band of a higher molecular weight. The origin of this 
 
Protein 
peak 
Fraction 
number 
A 
B C 
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band was unknown and was sent for identification via mass spectrometry. Reported results 
indicated it was a protein found in E. coli. As this band was found in all lab preparations of 
the recombinant PLY it was concluded that this band was most likely found in the original 
purified WTPLY that was used to create the polyclonal primary antibody used in these 
western blots and is therefore visible on the blot. 
 
Figure 3.3: Successful purification of wild type pneumolysin batch WTPLY NC-01 A: 
Coomassie gel for purified WTPLYNC-01. B: Western blot for purified WTPLYNC-01.  
WTPLY NC-01 added at 0.181mg/ml and positive control added at 0.1065mg/ml. Red arrows 
on Coomassie gel and western blot point to protein of interest, WTPLY at expected molecular 
weight of 57kDa. 
3.1.2 Generation of pneumolysin negative vehicle 
 A negative vehicle, the solvent of the purified toxin preparation with the His-
tagged pneumolysin removed was then generated as described in section 2.1.4 to serve as a 
negative control in all the cell based assays using the purified toxin. This means that the cells 
in future experiments will be subjected to anything in the protein preparation except for the 
pore forming toxin allowing for the distinction between effects that occur due to a possible 
contaminant such as LPS and PLY itself.  
Quality checks for purity and haemolytic activity were performed to determine if the WTPLY 
was successfully removed. A Coomassie gel and western blot using the neat preparation can 
be seen in Figure 3.4 labelled as Negative Vehicle. The Coomassie gel did not show any 
A B 
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bands of protein and no band could be seen on the western blot. The concentration of protein 
in the negative vehicle was then determined by the Nanodrop. The negative vehicle 
concentration was determined as 0.08mg/ml.  
 
Figure 3.4 Quality control testing for negative vehicle and nickel elution generated from 
WTPLY-NC-01 A. Coomassie gel for WTPLY-NC-01, eluted protein and negative vehicle. 
B: Western blot for WTPLY-NC-01, eluted protein and negative vehicle. Purified wild type 
pneumolysin (WTPLY-NC), Pneumolysin eluted from magnetic nickel beads (Ni Elute), 
Negative vehicle created using nickel beads (Negative Vehicle) and dH2O negative control 
(Negative Control). All protein loaded at the original purified concentration. Red arrow points 
to a high molecular weight band found only in the eluted protein. 
To recover the protein, magnetic nickel beads are used to bind the His-tag on the 
recombinant pneumolysin. The protein is eluted off using the same nickel affinity 
chromatography elution buffer used during the original protein purification. In theory, the 
imidazole eluted PLY should be fully functional and approximately the same concentration as 
the WTPLY used to make the negative vehicle. The purpose behind eluting the PLY protein is 
so it could be added to cell based assays to show that the PLY is unaffected by the process of 
generating a negative vehicle. The western blot for the eluted protein can be seen in Figure 
3.4, labelled as Ni Elute. The eluted PLY has a similar Coomassie profile to WTPLY NC-01. 
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However, western blot profile showed high molecular weight band that was absent from 
WTPLY NC-01 [Figure 3.4 Red arrow]. 
3.1.3 Haemolytic assays to test the functionality of purified, recombinant PLY 
Haemolytic assays were then performed on PLY, the negative vehicle and the eluted 
PLY as described in section 2.2.1. These assays are to test if PLY is functional as a pore 
forming toxin. Figure 3.5 A shows an image of the haemolytic assay performed on the 
purified PLY, its vehicle and the elute PLY. This assay has both a qualitative result, as seen 
by the pellets within the 96 well plate, and a quantitative result, which is determined by first 
centrifuging the 96 well plate, then collecting the supernatant from the top of each well and 
reading the absorbance in a plate reader. Where little or no lysis of the red blood cells occurs a 
small red pellet can be seen in the well. Where lysis does occur, such as when PLY is fully 
functional there will be no pellet visible. A standard control of pneumolysin (marked as 
WTPLY CD in the haemolytic assay below) was always used when testing the haemolytic 
functionality of a newly purified batch of PLY. The WTPLY toxins were added at an 
approximate 1 in 1000 dilution for a final concentration of 1μg/ml before adding to the PBS 
to create the necessary dilutions. Both the control and newly purified WTPLY preparations 
were found to have similar haemolytic ability (Figure 3.5 A). The negative vehicle, which is 
added without dilution into the assay, closely resembles the negative control of DPBS (Figure 
3.5 A). 
The endpoint, representing 50% lysis, is the well in the haemolytic assay which has 
approximately half a pellet of erythrocytes. WTPLY NC-01 and the lab stock pneumolysin 
both reached 50% lysis in well 5 (Figure 3.5 A). This gives a specific activity of 6.4 x 10
5
 
HU/mg for both WTPLY preparations tested. 
A second haemolytic assay was performed using DPBS as a negative control and 
WTPLY NC-01 as a positive control to test the WTPLY eluted from the nickel magnetic 
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beads (Figure 3.5 B). The eluted WTPLY added at 1μg/ml was found to have no haemolytic 
activity. The lack of functionality would have to be further investigated as there is no clear 
reason as to why this occurred  
 
 
Figure 3.5: Haemolytic analysis of WTPLY NC-01, negative vehicle and nickel elution 
A: Negative control (dPBS), positive control purified wild type pneumolysin from lab stock 
(WTPLY CD), purified wild type pneumolysin (WTPLY NC-01) and negative vehicle from 
nickel beads (Neg Vehicle). B: Pneumolysin protein eluted from magnetic nickel beads (Ni 
Elute)  
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Figure 3.6 Haemolytic proficiency of WTPLY NC-01, nickel elute and negative vehicle. 
A: Graph of percent lysis of erythrocytes by the WTPLY proteins. Concentration of toxin 
added was 0.25 µg/ml in lane 1 and was serially diluted across the 12 wells. The 
concentration is halved in each subsequent dilution. B: Graph of percent lysis of erythrocytes 
by Negative Vehicle 100% lysis set to absorbance of lysis caused by highest concentration of 
lab stock WTPLY at a concentration of 0.00025 mg/ml. Background lysis set to average 
absorbance of DPBS controls. Concentration of negative vehicle added was 0.08 mg/ml in 
lane 1 and was serially diluted across the 12 wells. The concentration is halved in each 
subsequent dilution. No error bars shown as n=1 for this experiment. 
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 To quantitatively compare the haemolytic property of the WTPLY proteins, the 
percent lysis was calculated and graphed as shown in Figure 3.6 A. The values for the three 
WTPLY proteins were compared on the same graph as the concentrations used in the 
haemolytic assay were the same. The percent lysis of erythrocytes in positive control WTPLY 
(WTPLY CD) was similar in value compared to the purified WTPLY NC-01. In contrast, the 
WTPLY which was eluted from the nickel beads caused almost no lysis. In fact, when 
measured against the background of DPBS some of the percent lysis values for eluted PLY 
preparation are negative. The negative vehicle percent lysis was plotted on a separate graph as 
this preparation was added to the haemolytic assay undiluted resulting in different 
concentrations. The percent lysis for the negative vehicle can be seen in Figure 3.6 B. As 
expected from the qualitative results of the haemolytic assay the negative vehicle showed no 
lysis when compared to the background negative control of DPBS.  
3.1.4 Purification of Δ6PLY 
 The protein Δ6PLY was generated as described in Kirkham et al. (2006), by inducing 
a double amino acid deletion of the alanine at position 146 and the arginine at position 147 
using a site directed mutagenesis kit (Kirkham, 2006). The deletion of these amino acids in 
Δ6PLY results in a loss of the haemolytic ability seen in WTPLY.   
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Figure 3.7: Successful purification of Δ6PLY A) Coomassie gel depicting chosen fractions 
eluted from the NAC column. Red arrow indicates protein of interest B) Coomassie gel 
depicting chosen fractions eluted from the AEC column Red arrow indicates protein of 
interest C) Western blot using anti-PLY rabbit polyclonal antibody and Odyssey visualization 
with anti-rabbit 800 secondary. Lane assignments 1) 1.81μg/ml WTPLY 2) 1.17μg/ml Δ6PLY 
3) SeeBlue2 protein ladder D) Graph of haemolytic assay supernatant absorbencies compared 
to DPBS control supernatant 
As with WTPLY, nickel affinity chromatography was chosen to extract the protein as 
Δ6PLY also has an incorporated his-tag. This again was followed by anion exchange 
chromatography which was used to purify out contaminants, such as LPS. The protein 
concentration was read by small volume spectrophotometer, Nanodrop. Quality control 
checks were performed as in WTPLY to verify purity and determine haemolytic properties. 
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3.1.5 Δ6eGFPPLY 
The protein Δ6eGFPPLY was generated as described in the PhD thesis of Dr. Graeme 
Cowan (Cowan, 2006). An enhanced green fluorescence protein (eGFP) gene was cloned into 
the already established pET33b vector expressing Δ6PLY created by Kirkham et al. (2006) to 
fuse the GFP protein to the N terminal end of Δ6PLY. This was to avoid the large fluorescent 
molecule interfering with the binding of the protein that occurs via domain 4 on the C-
terminal end of the protein.  
 
Figure 3.8: Successful purification of Δ6eGFPPLY A) Coomassie gel depicting chosen 
fractions eluted from the NAC column. Red arrow indicates protein of interest B) Coomassie 
gel depicting chosen fractions eluted from the AEC column. Red arrow indicates protein of 
interest. C) Western blot using anti-PLY rabbit polyclonal antibody and Odyssey 
visualization with anti-rabbit 800 secondary. Lane assignments 1) 1.81μg/ml WTPLY 2) 
SeeBlue2 protein ladder 3) 1.12μg/ml Δ6eGFPPLY D) Graph of haemolytic assay supernatant 
absorbencies compared to DPBS control supernatant 
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The Δ6eGFPPLY protein purification was completed using nickel affinity 
chromatography to extract the protein as it has an incorporated his-tag and anion exchange 
chromatography to purify out contaminants has an incorporated his-tag its purification, such 
as lipopolysaccharide (LPS). The protein concentration was determined by Nanodrop and 
used in various quality control assays including a haemolytic assay to ensure it does not have 
haemolytic properties and a Western blot to visualize purity (Figure 3.8). 
3.2 Cell Based Assays 
3.2.1 LDH and MTT assays in L929 fibroblast cells 
 In order to identify sublytic concentrations of WTPLY for use in further experiments, 
cell based assays using fibroblasts were used. These cells were used as they are easy to grow 
and were previously used by the research group so the results could be compared between 
batches of toxin. The assays using these cells will serve not only as a quality control but also 
as a guide for what concentrations of WTPLY NC-01 cause cell death above 5%. Lactate 
dehydrogenase (LDH) assays are one type of assay used. LDH assays are used to determine 
cytotoxicity of cells by analysing the levels of the LDH enzyme, an enzyme normally found 
in the cytoplasm which is released from the cell into the supernatant upon cell lysis (described 
in 2.2.2). However, in the case of large pore forming toxins such as pneumolysin, the LDH 
assay determines cell permeability as the pores created are large enough to allow the LDH 
enzyme to exit without complete cell lysis. Another type of assay used, MTT assays, are cell 
viability assays. MTT assays measure formazan, an insoluble purple compound, which is the 
product of the conversion of MTT by cell mitochondria. This conversion process to formazan 
can only proceed when the cell is alive and if a cell is dead the MTT compound remains its 
original yellow colour (described in 2.2.3). 
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Figure 3.9 Results of varying pneumolysin concentrations on the membrane 
permeability and viability of L929 fibroblast cells A) LDH Assay for L929 fibroblast cells 
exposed to toxin or negative vehicle for either 3 or 6 hours. Lysis buffer was used as 100% 
lysis and media only negative control was used as background to determine percent lysis. 
Positive control described as, bovine heart LDH, was issued by the manufacturer to ensure 
performance of the kit. Error bars indicate standard deviation between experiments as n=2. B) 
MTT Assay for L929 fibroblast cells exposed to toxin or negative vehicle for 3 or 6 hours. 
Lysis buffer set the value for 100% cell death. Media only wells used as one of the negative 
controls provided the value for background. The results shown are from a single replicate, 
n=1. 
The graphical results for both the LDH and MTT are similar.  A concentration of 
10μg/ml of WTPLY NC-01 resulted in 100% cell lysis in the LDH assay and in the MTT 
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assay resulted in 75% cell death by 3 hours and 93.5% cell death by 6 hours. At 0.5μg/ml the 
percent of dead and lysed cells decreased to less than half the cells tested. At 0.1μg/ml, the 
expected sublytic concentration as recorded in literature, a low percent of cell lysis, 7.44%, 
was seen even after 6 hours of exposure to the toxin. The negative vehicle (preparation 
described in 2.1.4) had a maximum cell lysis of 2.55% after 6 hours at 0.05μg/ml and a 
maximum cell death of 19.5% at a concentration of 0.1μg/ml after 3 hours exposure in L929 
cells.  
3.2.2 LDH assays in A549 lung epithelial cells 
 Lactate dehydrogenase (LDH) assays were used to determine the cytotoxicity that 
occurs in A549 lung epithelial cells when exposed to different concentrations of wild type 
pneumolysin in order to determine sublytic concentrations of the toxin. This colorimetric 
assay detects the LDH enzyme, which is usually found in the cell cytoplasm but releases into 
the supernatant when the cell undergoes lysis. The full method used is detailed in Section 
2.2.2. 
A549 cells were exposed to the wild type toxin or a negative vehicle for 3 or 6 before 
the supernatant was removed. The supernatants were then analysed by plate reader and the 
percent lysis was determined. The lysis buffer supplied by the manufacturer was used to set 
the 100% lysis value and the media only control was used to set the background absorbance 
value. Sublytic concentrations are defined as less than 5% cell lysis. According to the results, 
the pneumolysin concentration with a percent lysis that fit the sublytic criteria was a 
concentration of 0.1μg/ml or 1.8µM. The negative vehicle which served as the negative 
control recorded percent lysis in the negative figures for most of concentrations tested 
indicating that no cytotoxicity occurred in these cells for the time exposed. 
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Figure 3.10:Effect of WTPLY NC-01 on the Membrane Permeability of A549 Lung 
Epithelial Cells. A549 lung epithelial cells were exposed to wild type pneumolysin toxin or 
negative vehicle for 3 or 6 hours before the supernatant was removed for analysis. Lysis 
buffer was used as 100% lysis and media only negative control was used as background to 
determine percent lysis. Positive control described as, bovine heart LDH, was issued by the 
manufacturer to ensure performance of the kit. Error bars indicate standard deviation between 
experiments as n=3. Statistical signficance indicated by *** (p<0.005). 
3.3 Determining sublytic pneumolysin concentrations in A549 lung epithelial cells 
3.3.1 Confocal microscopy using eGFPPLY 
 While cell based assays provide a quantitative measurement for the damage wild type 
PLY was doing to A549 lung epithelial cells, confocal microscopy was used to provide 
qualitative analysis. Wild type PLY labelled with eGFP (eGFPPLY) was utilized as described 
in section 2.4.1 so that both cell morphology and toxin localization could be seen. The 
sublytic concentration for WTPLY is 1.8µM as found by LDH assay in section 3.2.2 above. 
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 At a concentration of 1.1µM of eGFPPLY [Figure 3.11 A and B] the A549 cells were 
adhered to the slide with no obvious membrane blebbing or rounding both of which are 
markers of apoptosis. When the concentration of eGFPPLY was increased 10 times to 
11.1µM of eGFPPLY [Figure 3.11 C and D] some of the cells began to show evidence of 
apoptosis and cell lysis. Figure 3.10 LDH assay results support this as there is a rise in LDH 
release when PLY is at 1.0μg/ml over the sublytic concentration of 0.1μg/ml. The majority of 
cells exhibited membrane blebbing and their morphology appeared rounded as the cells began 
detaching from the slide. Although in the minority, there were a few cells that still appeared 
normal and undamaged at this concentration.  At 
the 111.5µM [Figure 3.11 E and F] concentration 
of eGFPPLY most of the cells were rounded and 
dead. Some evidence of nuclear disruption can be 
seen as indicated by a decrease in the DAPI 
staining shown in blue. The remaining cells were 
in the process of apoptosis as evident by extensive 
membrane blebbing.  
Figure 3.11: Effects of eGFPPLY toxin on A549 
lung epithelial cells. A eGFPPLY added at a 
concentration of 1.1µM B) eGFPPLY added at a 
concentration of 11.1µM. C) eGFPPLY added at a 
concentration of 111.5µM. In all conditions toxin 
was added and cells were incubated for 30 minutes 
at 37
o
C and 5% CO2 before fixation. Red arrows 
indicate cells with evidence of membrane blebbing 
and yellow arrows indicate cells with evidence of 
cell rounding. Images were taken via confocal 
microscopy at 60x magnification under oil 
immersion. Blue staining corresponds to nuclei 
stained by DAPI and green staining corresponds to 
eGFP conjugated pneumolysin toxin. 
A 
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3.4 Effects of PLY and Δ6PLY toxoid in A549 lung epithelial cells 
3.4.1 Live cell microscopy using Δ6eGFPPLY 
 To determine whether the Δ6eGFPPLY toxin would have any adverse effects on the 
A549 lung epithelial cells that would cause variation in using it as a non-haemolytic control, a 
simple experiment in which monolayers of A549 cells were exposed to the toxin 30 minutes 
before visualisation without a fixation step was performed [Figure 3.12]. Although the lack of 
cytotoxicity of Δ6eGFPPLY was previously demonstrated for another cell type, L929 
fibroblast cells in the study by Kirkham et al (2006) but this experiment was performed to 
ensure relevance for this project’s cell type of interest. 
 All images were taken at 20x and 40x magnification as oil immersion cannot be used 
in conjunction with live cell imaging which caused difficulty in seeing the exact localisation 
of the toxin on the cells. The low magnification also proved difficult as there was a lack of 
fluorescence signal from some of the lower concentrations of toxin causing the image to look 
faint [Figure 3.12]. What was obvious was that even at concentrations 100x greater than that 
of a lethal dose of WTPLY [Figure 3.12], the Δ6eGFPPPLY toxin did very little to effect the 
morphology of the A549 cells indicating its lack of cytotoxic effects[Figure 3.12 H-J]. 
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Figure 
3.12: 
Live cell 
fluoresce
nce 
imaging 
of the 
effects of 
Δ6eGFP
PLY 
toxin on 
A549 
Lung 
Epithelia
l Cells. 
A549 
cells were 
grown to 
a 
monolaye
r in a 24 
well plate 
before 
being 
exposed 
to 
varying 
concentra
tions of 
Δ6eGFPP
LY for 30 
minutes. 
The cells were washed and colourless RPMI was added before immediately being visualised 
by fluorescence microscopy at 20x or 40x magnification. A) Bright field image of control 
cells not exposed to Δ6eGFPPLY at 40x magnification B) Bright field image of A549 cells 
exposed 1.8µM of Δ6eGFPPLY at 40x magnification. C-D: A549 cells exposed to 18.1µM of 
Δ6eGFPPLY C) Bright field image at 40x magnification.  D) Fluorescence image at 20x 
magnification. E-G: A549 cells exposed to 180.6µM of Δ6eGFPPLY E) Bright field image at 
40x magnification. F) Fluorescence image at 20x magnification. G) Fluorescence image at 
40x magnification. H-J: A549 cells exposed to 1.8mM of Δ6eGFPPLY H) Bright field image 
at 40x magnification. I) Fluorescence image at 20x magnification.  J) Fluorescence image at 
40x magnification. 
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3.4.2 Immunostaining of F-actin, E-cadherin and eGFP labelled toxin in A549 cells 
          To investigate the possible roles of E-cadherin and actin in invasion, preliminary 
immunofluorescence was performed by staining A549 cell monolayers with E-cadherin and 
actin antibodies in absence of any toxin. This allowed for the optimization of the microscopy 
staining protocol before the addition of any experimental elements.  
 As described in the Methods and Materials [section 2.5.1], A549 cell monolayers were 
fixed, permeabilized and stained with E-cadherin to visualize cell-cell contacts. The results 
are shown in the representative image in Figure 3.13. It should be highlighted that even at 
very high primary and secondary concentrations of antibody, as well as high gain set on the 
microscopy software, the E-cadherin fluorescent signal was very low and cell to cell contacts 
were barely visible. The staining was also inconsistent across the monolayer.  
Figure 3.13: E-cadherin 
immunostaining of A549 cells. A549 
lung epithelial cells were grown to a 
monolayer on a coverslip before being 
fixed and stained with 1 in 50 dilution 
of E-cadherin primary antibody and 1 
in 500 dilution of Alexa Fluor 633 
secondary antibody. Coverslip was 
imaged by confocal microscopy at 60x 
magnification using oil immersion. 
Blue staining corresponds to nuclei 
stained by DAPI (example marked by 
blue arrow) and red staining 
corresponds to E-cadherin 
immunostaining (examples marked by 
red arrows). 
 After the initial E-cadherin immunofluorescence experiments, the second component 
of the triplex immunostaining, F-actin, was tried to test the staining potential of the 
immunofluorescence protocols. To accomplish this, a fluorescence conjugated phallodin 
antibody was utilized [Materials and Methods 2.5.2]. Figure 3.14A depicts the results of 
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staining A549 monolayers for F-actin fibres which were clearly seen in all of the cells. A 
bright field image was used as a control to visualize the cell morphology and can be seen in 
Figure 3.14B. The bright field images show the A549 cells had no obvious morphological 
abnormalities as a result of the immunofluorescence protocol.  
 After confirmation of the immunofluorescence protocol by actin staining, toxin 
exposure was combined with the F-actin staining to try to optimize a dual staining technique 
and get an idea of the possible localisation of PLY and Δ6PLY toxin in respect to A549 cells. 
A control of toxin exposure without actin staining was performed using 2.2µM of eGFPPLY 
which was applied throughout this experiment to discern if any evidence of cytotoxicity to the 
cells could be seen [Figure 3.14 C and D]. The higher concentrations of eGFPPLY, 11.1µM 
and 111.5µM [Figure 3.11 D and F], have obvious cytotoxic effects, while, the bright field 
image of cells exposed to 2.2µM of eGFPPLY [Figure 3.14 D] showed no evidence of 
apoptotic effects such as rounding or membrane blebbing. 
 A sublytic concentration of 2.2µM of eGFPPLY and 2.2µM of Δ6eGFPPLY, A549 
cells were exposed to the respective toxin before fixation, permeabilization and staining for F-
actin. The microscopy images of the experiments using these two toxins are as shown in 
Figure 3.14 E-F for cells exposed to eGFPPLY and Figure 3.14 G-H for cells exposed to 
Δ6eGFPPLY. The F-actin staining seems to be brighter in the case of the non-haemolytic 
Δ6eGFPPLY exposure compared with the conjugated wild type toxin, eGFPPLY. The images 
show the majority of the eGFP staining is located near the nucleus of the cells for both the 
conjugated wild type toxin and the non-haemolytic variant [Figure 3.14 E and G marked by 
yellow arrows]. The eGFPPLY exposed cells appearing to have a greater amount of toxin 
staining. Both bright field images prove the A549 cells themselves had no adverse effects due 
to toxin exposure as the cell morphology of the monolayers appeared normal [Figure 3.14 F 
and H]. 
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Figure 3.14: 
Immunofluorescence staining of 
F-actin after exposure of A549 
cells to either eGFPPLY or 
Δ6eGFPPLY. A549 lung 
epithelial cells were grown to a 
monolayer on a coverslip before 
the appropriate samples were 
exposed to the corresponding 
toxin for 30 minutes at 37
o
C and 
5% CO2. Cells were then fixed and 
were appropriate stained with 1 in 
500 dilution of Alexa Fluor 
Phalloidin 555 antibody to detect 
F-actin. A-B) Control slide for F-
actin staining of A549 without 
exposure to toxin. Images were 
taken in confocal fluorescence and 
bright field. C-D) Control slide for 
2.2µM eGFPPLY toxin exposure 
without F-actin staining. Images 
were taken in confocal 
fluorescence and bright field. E-F) 
Slide with A549 cells exposed to 
0.2μg/ml eGFPPLY then fixed and 
stained for F-actin. Images were 
taken in confocal fluorescence and 
bright field. G-H) Slide with A549 
cells exposed to 2.2µM 
Δ6eGFPPLY then fixed and 
stained for F-actin. Images were 
taken in confocal fluorescence and 
bright field. Coverslip was imaged 
by confocal microscopy at 60x magnification using oil immersion. Blue staining corresponds 
to nuclei stained by DAPI, green staining corresponds to eGFP conjugated toxin (examples 
marked with yellow arrows) and red staining corresponds to actin immunostaining.  
The A549 cells visualized under 60x magnification showed no obvious signs of 
colocalization of PLY toxin with actin fibres. This may be due to the use of a lower resolution 
in this experiment than used in the study by Hupp et al. 2012 which found colocalization of 
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PLY with actin (Hupp, 2012). The lower resolution led to the toxin particles not being distinct 
enough to really see where they are attached but instead show as green specks dispersed 
amongst the cell. 
 
 
Figure 3.15: High 
magnification of 
F-actin staining 
after A549 
exposure to either 
eGFPPLY or 
Δ6eGFPPLY. 
A549 lung 
epithelial cells 
were grown to a 
monolayer on a coverslip before being exposed to the corresponding toxin for 30 minutes at 
37
o
C and 5% CO2. Cells were then fixed and stained with 1 in 500 dilution of Alexa Fluor 
Phalloidin 555 antibody to detect F-actin. A) Slide with A549 cells exposed to 3.3µM 
eGFPPLY then fixed and stained for F-actin. Images were taken in confocal fluorescence and 
bright field. B) Slide with A549 cells exposed to 11.1µM Δ6eGFPPLY then fixed and stained 
for F-actin. Images were taken in confocal fluorescence and bright field. Coverslip was 
imaged by confocal microscopy at 100x magnification using oil immersion. Blue staining 
corresponds to nuclei stained by DAPI, green staining corresponds to eGFP conjugated toxin 
and red staining corresponds to actin immunostaining. 
In order to visualize using a 100x oil immersion lens, cell monolayers were again 
grown and exposed to toxin before immunostaining for F-actin. A concentration of 3.3µM 
eGFPPLY, the maximum that could be used without causing cytotoxicity, was added to A549 
lung epithelial cells. The results for the exposure to conjugated wild type toxin are shown in 
[Figure 3.15A]. The Δ6eGFPPLY was added at a much higher concentration of 11.1µM to the 
A549 cells as this version of the toxin was not found to cause haemolysis. The concentration 
was increased with the Δ6eGFPPLY compared to the eGFPPLY to test whether more distinct, 
bright toxin aggregations could be seen. The results are depicted in Figure 3.15 B. Neither 
A B 
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toxin exposures even at 100x magnification resulted in the distinct colocalization seen in the 
Iliev research group paper (Hupp, 2012).  
3.4.3 Western blotting for E-cadherin and actin in A549 whole cell lysates 
 Due to the weak E-cadherin immunofluorescence staining, it was decided to test for E-
cadherin protein levels in A549 whole cell lysates to determine if adequate levels of the 
protein existed in the monolayers being stained for microscopy. Section 2.6 in the Materials 
and Methods details the process for Western blotting followed. Figure 3.19 shows the results 
of a Western blot run using protein from A549 whole cell lysates and probed for E-cadherin 
and actin. Actin was used a loading control in the experiment to ensure that any change in E-
cadherin seen were not just due to more protein being added. By utilizing two different 
secondary conjugated proteins and the Licor Odyssey Infrared Imaging system, both actin and 
E-cadherin can be seen on the same membrane allowing for direct comparison. E-cadherin 
was labelled with a secondary antibody specific for mouse immunoglobins which could be 
visualized in the 800nm, green channel. Actin, which served as a control, was labelled with a 
secondary antibody specific for rabbit immunoglobins which could be visualized in the 
700nm, red channel. The specific secondary antibodies allow for the protein of interest and 
control to be probed on the same membrane for greater accuracy of any deviations in the 
loading control. 
 The actin, loading control bands could be seen albeit in differing concentrations in 
every lysate loaded in red colour highlighted by the pink boxes at an approximate molecular 
weight of 42kDa [Figure 3.16]. E-cadherin bands, highlighted by the yellow boxes, were faint 
but could be seen at the approximate molecular weight of 100kDa in the sublytic, 0.1μg/ml 
pneumolysin treated cell lysates and the whole cell lysate controls made from A549 
monolayers [Figure 3.16]. A549 cells exposed to lytic concentrations of pneumolysin, 
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10μg/ml, were found to have no visible 100kDa band and therefore were found negative to E-
cadherin [Figure 3.16]. 
 
Figure 3.16 Effect of pneumolysin on E-cadherin in A549 whole cell lysates. A) Dual 
channel scan of 700nm and 800nm channels by Licor Odyssey Imager. B) Grey scale of 
800nm channel only, specific for E-cadherin antibody. C) Grey scale of 700nm channel only, 
specific for actin antibody. Lanes assignments: 1) SeeBlue2 prestained protein ladder 2) A549 
whole cell lysate by lysis buffer after 1 hour treatment with 0.1μg/ml PLY, supernatant 3) 
A549 whole cell lysate by lysis buffer after 1 hour treatment with 10μg/ml PLY, supernatant 
4) A549 whole cell lysate by lysis buffer after 1 hour treatment with 0.1μg/ml PLY, 
supernatant and cell debris 5) A549 whole cell lysate by lysis buffer after 1 hour treatment 
with 10μg/ml PLY, supernatant and cell debris 6) A549 whole cell lysate by lysis buffer, 
supernatant 7) A549 whole cell lysate by lysis buffer, supernatant and cell debris. E-cadherin 
bands are about 100kDa and are in the 800nm channel so they appear green (highlighted by 
yellow boxes). Actin loading control bands are about 42kDa and are in the 700nm channel so 
they appear red (highlighted by pink boxes). 
3.4.4 Effect of pneumolysin and polysaccharide capsule on adherence of S. pneumoniae 
to A549 lung epithelial cells 
 Adherence of S. pneumoniae to a host cell is the first stage in the invasion process. To 
determine the traits in this bacterium that lead to adherence, various strains of S. pneumoniae 
were tested in an adherence assay [Materials and Methods section 2.7] to assess how well 
each strain adhered to A549 lung epithelial cells, a common cell type encountered by this 
bacterium.  
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A graph showing the results of three replicate adherence assays can be found in Figure 
3.17. The acapsular strains of S. pneumoniae adhered better to the A549 cells than the stains 
which were surrounded by a polysaccharide capsule. The R6 acapsular, laboratory strain was 
found to adhere to A549 cells the best with an average percent adherence of 34.992%. Strong 
statistical significance exists between the adherence achieved by the acapsular R6 and all of 
the capsular serotype 2 D39 strains. 
 
Figure 3.17 Adherence of various S. pneumoniae strains to A549 lung epithelial cells. S. 
pneumoniae was added to monolayers of A549 cells at a density of 1x10
7
 bacteria/ml. Percent 
adherence was calculated by dividing the adhered bacteria recovered after washing the 
monolayers by the starting inoculum added. All counts were determined by serial dilution, 
viable counting. D39 = virulent, serotype 2, clinical isolate; D39 PLY STOP = D39 mutant in 
which the PLY gene has a premature stop codon resulting in a non-functional toxin; D39 
FP22 = acaspsualar D39 created by Pearce et al. 2002 by insertion of a kanamycin cassette 
deleting the capsule locus; R6 = acapsular, avirulent laboratory strain that is a descendent of 
the serotype 2 clinical isolate, D39 strain. Error bars depict standard deviation between 
experiments as n=3. Statistical significance depicted by *** (p<0.005). 
The ability to produce pneumolysin did not appear to affect adherence as no statistical 
significance was found between the adherence of D39 wild type and the PLY negative mutant 
D39 PLY STOP strain.  
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FP22, a knockout strain of D39 that does not produce a capsule, was found to adhere 
better to A549 cells than either of the capsular strains tested. The average percent adherence 
of FP22 was 9.693% rather than the 3.932% seen in D39 and 3.503% seen in the D39 PLY 
STOP strain. However, the difference in adherence between these three strains was not 
statistically significance. 
3.5 Optimisation of the Experiment Environment for Host-Toxin Interactions  
3.5.1 Introduction of pJWV25 plasmid into S. pneumoniae 
 The pJWV25 plasmid was created in a study by Eberhardt et al. in 2009. This plasmid 
contains a zinc inducible promoter, an ampicillin resistance gene, a tetracycline resistance 
gene and a gene for GFP+, which is a faster folding variant of GFP [Eberhart, 2009]. A 
plasmid map of pJWV25 is shown in Figure 3.18 A. The GFP+ gene can be linked to the N-
terminus of a protein of interest using a flexible linker region. There is a history of difficulty 
visualizing GFP in S. pneumoniae. This may be due to the acidic interior of the bacterium and 
the organism’s preference for a carbon dioxide rich environment. The Eberhardt et al. study 
showed the enhanced visibility of GFP+ over the commonly used GFP. The study explained 
how this new plasmid could be utilized in other studies involving S. pneumoniae. The 
pJWV25 plasmid incorporates into the S. pneumoniae genome by a double crossover event. 
The E. coli origin of replication and the ampicillin resistance gene are removed when the 
plasmid completes the double crossover event and successfully inserts into the S. pneumoniae 
genome. 
 The pJWV25 plasmid was transformed into S. pneumoniae as described in section 
2.3.4. Screening primers which identify the successful insertion of pJWV25 DNA into the 
pneumococcal chromosome by yielding a product with an expected size of 420bp were used 
in a PCR performed on the genomic DNA isolated from the transformants (described in 
2.3.5). The gel electrophoresis photo shown in Figure 3.18 B shows the result of the PCR 
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screen. The results clearly show one band for each of the two transformants tested at the 
approximate size of the expected PCR product.  
 
Figure 3.18: Insertion of pJWV25 plasmid into Streptococcus pneumoniae. A: Plasmid 
map of the pJWV25 plasmid from Eberhardt et al. 2009. ‘bgaA and ‘spr0564 are the genes 
that allow for insertion into the S. pneumoniae genome by a double crossover event. B: 
Electrophoresis gel of a PCR screen for pJWV25 in S. pneumoniae transformant gDNA. The 
expected product of the PCR was 420bp indicated by the yellow arrow. 
3.5.2 Production of Chemically Defined Media and Preliminary Growth Curves 
 In experiments designed to investigate cellular pathways, it is an invaluable tool to 
have a chemically defined media (CDM) that allows you to remove or add components in 
order to test various conditions. CDM should allow for bacterial growth curves that are 
comparable to the complex media that is commonly used to grow that organism. Another 
reason why CDM is so valuable as an experimental tool is due to the auto fluorescent nature 
of complex media. This attribute leads to complications when performing analysis on 
quantitative measurements that are meant to read the fluorescence of a conjugated toxin or 
genetically modified bacterium. 
 A chemically defined medium was made to the specifications found in the 
supplementary information in Appendix I. As the complete CDM is not stable for long 
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periods of time, the components are created in mass quantities then frozen to allow for 
replication. In the case of the following experiment a small batch of 100ml was used. 
 To test the CDM two well studied and characterized strains of S. pneumoniae, D39 
and TIGR4, were chosen as there is a variety of literature and mutants are available for each 
strain. D39 is a virulent serotype 2 strain first used by Fredrick Griffith in 1928. TIGR4 is a 
virulent serotype 4 clinical isolate first isolated by Aaberge in 1995. Either of these strains 
would provide a good genetic background for future experiments.  
Standard inocula in CDM were first made for both wild type S. pneumoniae strains, 
D39 and TIGR4, so there would be little to no carryover of nutrients from the complex 
medium into the growth curves. A growth curve was performed in a microplate reader with a 
duplicate culture growing in a 37
o
C water bath which allowed for viable counting (described 
in 2.3.1). The results of the duplicate culture grown in 10ml of either CDM or BHI complex 
media are shown in Figure 3.19 B and C. The results show that there was growth of both 
strains in both conditions at a steady rate as determined by CFU/ml calculated by viable 
counting. The cultures in BHI grew to a greater OD600 than the CDM cultures.  
 The growth curve from the plate reader (Figure 3.19A) showed very different results 
to the cultures grown in larger volumes of media in the water bath. The cultures in BHI were 
found to have a typical growth curve with a small lag phase, an exponential or log phase and a 
stationary phase around OD600 0.6 which is typical for S. pneumoniae as this is when autolysis 
begins. On the other hand, the absorbance profile for the strains grown in CDM did not 
resemble a typical growth curve. The D39 strain in CDM showed a short growth phase 
although this was much shorter the D39 grown in BHI. The cells grown in CDM died after 
only 4 hours of incubation. The TIGR4 strain did not appear to ever start growing properly in 
the CDM.  
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Figure 3.19 Growth Curve of CDM vs. BHI cultures A)Graph representing the growth of 
TIGR4 and D39 S. pneumoniae in either BHI or CDM over an 18 hour growth period in a 96 
well plate at 37
o
C and 5% CO2 B) Graph of the CFU/ml of S. pneumonaie strains grown in 
parallel with the plate reader experiment. These were grown in a 37
o
C water bath from the 
same OD600 0.6 standard inoculum added to the 96 well plate. 
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Chapter 4: Discussion 
4.1 Purification of proteins 
A goal of pneumococcal research is the development of therapeutic agents such as 
new antibiotics and vaccines to aide in curing and preventing pneumococcal disease 
throughout the world. An important part of this process is to understand the interactions of the 
Streptococcus pneumoniae with the host cell. By illuminating the various effects the 
bacterium has on its host, one can target virulence factors or processes that lead to disease. In 
the case of Streptococcus pneumoniae, the pore forming toxin it produces, pneumolysin, has 
been shown to be important in the pathogenesis of disease caused by this organism. PLY has 
been found to be important for the growth of the bacteria in vivo as well as for the overall 
survivability of the host once infection has occurred (Benton, 1995; Berry, 1989). Not only is 
PLY an important virulence factor of the S. pneumoniae,  it has  also been identified for its 
potential use in vaccine development due to its existence in almost all clinical isolates of 
pneumococcus, this may allow for the development of a non-serotype specific pneumococcal 
vaccine (Kadioglu, 2008).  
As S. pneumoniae produces many virulence factors which aid in its capacity to cause 
disease, the first step in elucidating PLY specific effects was to purify the toxin itself for use 
in various experiments that would allow for the testing of the effects of the toxin alone. Once 
a protein is purified, various quality checks must be also be performed to ensure that the 
purified protein is the expected size, there are no obvious contaminants and is functional 
before moving forward with experimentation. As shown in results sections 3.1, western blots 
and Coomassie gels were run during and after the purification process using a polyclonal 
primary antibody targeted to pneumolysin.  The protein purified was found to be 
approximately 57kDa in size, which was the expected size taking into account the size of the 
protein pneumolysin at 53kDa and the added His-tag.  Although the protein preparation seems 
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clear of obvious contaminations, silver staining was also performed (not shown) to have 
increased sensitivity. A small spectrum of faint bands of various sizes did appear in silver 
staining. It is advised that the use of AEC for purification should remove the negatively 
charged LPS but specialized LPS testing would have been preferable due to the focus of this 
project on PLY and the fair amount of protein purified. If the LPS test showed any 
contamination, purification direct from S. pneumoniae may have to be investigated. Direct 
purification from S. pneumonaie would be more costly for time and resources and would 
result in a loss of ability to compare the purified batch to that of other lab stocks, which are 
recombinant protein. 
As LPS is a common contaminant in E. coli based protein purification, a negative 
control was required to use in all cell based experiments. This negative vehicle would be the 
protein preparation minus the pneumolysin protein itself. The method of using magnetic 
nickel beads yielded a small batch of negative vehicle which was tested against a polyclonal 
antibody for pneumolysin in a western blot (Figure 3.4) The technique of generating a 
negative vehicle in larger batches so no variation could come into experimentation would 
have to be considered if a more in depth project arises from the foundations of this one. Also 
still unknown is why the pneumolysin protein eluted from the magnetic nickel beads was non 
haemolytic although this lack of functionality may be due to an interaction between 
pneumolysin and the imidazole in the elution buffer. Another possible explanation for the lack 
of haemolytic ability could be due to aggregation of pneumolysin monomers. The aggregates 
may prevent the protein from binding or changing conformation, both of which are important 
for the haemolysis of eukaryotic cells. Aggregation may also be the cause of the marked 
higher molecular band seen in Figure 3.4 which occurred in the pneumolysin eluted from the 
nickel beads. Also of note is the smearing that occurred in the lane of the gel where the 
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protein eluted from the nickel beads ran (Figure 3.4). This effect may be due to denaturation 
of the protein from excess time at room temperature. 
 To determine the functionality of PLY a combination of haemolytic assays and cell 
based toxicity assays were performed. The result of the haemolytic assays for PLY is shown 
qualitatively in Figure 3.5 and quantitatively in Figure 3.6. The haemolytic activity of 
WTPLY NC-01 was calculated as is standard when purifying pneumolysin and was found to 
be 6.4 x 10
5
 HU/mg. However, a study by Benton et al. in 1997 suggested that the value of 
haemolytic activity of PLY did not affect the pneumococcal strains virulence or growth in an 
in vivo model of disease (Benton, 1997). So although many studies identify this value as part 
of the purification process haemolytic activity is perhaps more useful when it comes to 
comparing different structural mutants to identify how changes within the PLY sequence 
could change its function as a pore forming toxin. 
 Due to its toxicity to cells, PLY itself would not be safe to use in vaccine development 
so for both research and clinical purposes many truncated or mutated versions of PLY have 
been created that prevent its full functionality as a pore forming toxin. Some of the toxoids 
that have been created are, pdT (Berry, 1995), plD1 [PdH367] (Berry, 1995), plD2 (Goulart, 
2013), and PdB (Paton, 1991). One toxoid version of PLY, named Δ6PLY due to a deletion of 
the 146
th
 and 147
th
 amino acids of the pneumolysin sequence, was developed by Kirkham et 
al in 2006 and had characteristics that would make it an ideal candidate for vaccine 
development (Kirkham, 2006). Δ6PLY was found to not be cytotoxic even at concentrations 
of 1000 times that of WTPLY. It was also discovered that the toxoid did not form functional 
pores but retained the immunogenic effects of PLY. This means that antibodies can be raised 
against PLY resulting in host protection without the damage caused by the wild type toxin 
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making this toxoid an invaluable tool for vaccine candidates and research studies involving 
living cells and tissues (Kirkham, 2006). 
 A variant of the Δ6PLY toxoid was produced by another member of the Mitchell lab, 
Graeme Cowan as detailed in his PhD thesis (Cowan, 2006). This variant, named 
Δ6eGFPPLY is an eGFP conjugated version of the toxoid that provides a tool for cell studies 
involving microscopy as the toxoid will be able to be easily visualized in the green 
fluorescence channel at eGFP’s optimum wavelengths for excitation and emission of 488/509. 
The fluorescence conjugation grants the ability to track the toxoid in a live system and to 
perform various localization studies. 
 The aim of this research project was to determine host-pathogen interactions in the 
context of the pore forming PLY. The ability to utilize the Δ6PLY toxoid and its eGFP 
conjugated version, Δ6eGFPPLY, provides a useful tool in determining which effects are 
caused as a result of the pore formation or cytotoxicity of the wild type toxin compared to 
effects caused due to immune response cascades which are triggered by both the wild type 
toxin and the toxoid.  
 The purification process for both proteins resulted in high yields of each protein, 
approximately 18.5mg for Δ6PLY and 35mg for Δ6eGFPPLY. These proteins were diluted to 
approximately 1.0mg/ml stocks and frozen until required to prevent degradation. The quality 
control tests shown in Figures 4.7 and 4.8 came back with a strong band of each protein at the 
projected molecular weights and a lack of haemolytic activity which is expected for these 
toxoids as previously characterized by previous lab members (Kirkham, 2006; Cowan, 2006). 
These results provide a solid foundation for the use of these proteins in experiments with the 
confidence that they are relatively pure and functioning as expected. 
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4.2 Determining sublytic concentration of WTPLY  
Much of the existing research on PLY is based upon the effects of PLY when it is at 
lytic concentrations in the host. This project was aimed more at how the host responds when 
PLY is present but at sublytic concentrations. To identify what dose of toxin was sublytic, cell 
based assays were performed to test the cytotoxicity of the WTPLY prepared. The lactate 
dehydrogenase assay is a commonly used assay to determine the permeability of cell 
membranes in response to toxin (Aguilar, 2009; Förtsch, 2011). LDH assays were used to test 
the membrane permeability due to pore formation and the results compared with MTT assays 
which are cell live/dead assays. The first type of cells used in these assays was L929 
fibroblast cells which were chosen to test the method used as the cells are easy to grow and 
work with and allowed for comparison of the results to previous studies to further validate the 
WTPLY preparation. The MTT and LDH assays both showed sublytic concentrations of PLY 
to be approximately 0.1μg/ml (Figure 3.9). At this concentration, there was minimal cell death 
and almost no cell lysis. The concentration found in the results also agrees with sublytic 
concentrations used in studies in the literature (Iliev, 2007).   
 Distinguishing between lytic and sublytic concentrations of pore forming toxins is 
critical when applying lytic toxins to cells in the study of the effect of the toxin on triggering 
host cell pathways without killing the cells. If the concentration added to any experiment is in 
the lytic range of the toxin then the host cells will initiate pathways that are involved in 
committed death of the cell, where if a sublytic concentration of the toxin is added to an 
experiment the host cell may initiate more inflammation and emergency recovery pathways in 
an attempt to survive the attack. A study by Babiychuk et al. (2009) looks into the difference 
in commitment of host cells to apoptosis and death in response to streptolysin O, a member of 
the cholesterol dependent cytolysin pore forming toxin family related to pneumolysin. This 
study investigates the ability of a cell to cope with varying concentrations of streptolysin O 
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and shows that at certain concentrations the toxin overwhelms the host cell. The cell is 
therefore unable to repair itself leading to prolonged periods of ion oscillations or even cell 
death (Babiychuk, 2009).  
 Another important factor to consider is the concentrations of toxin that would be 
found in infection and if these would be really as high as the concentrations used in most 
studies in vitro. If the concentrations vary significantly the results of the experiments 
performed will not reflect what is happening in the live system. 
 The LDH assays applied to A549 cells showed that the sublytic concentration when 
applied to lung epithelial cells for the batch of pneumolysin purified for this MSc was 
0.1μg/ml [Figure 3.10]. This concentration agrees with the sublytic concentration described in 
many published articles as well as the L929 fibroblast experiments performed and will 
therefore be the concentration utilized in future experiments (Aguilar, 2009; Iliev, 2007; 
Förtsch, 2011; Shin, 2010). 
4.3 Cytotoxic effects of PLY and Δ6PLY toxoid in A549 lung epithelial cells 
Microscopy was performed to give a qualitative rather than quantitative evaluation of 
the effects of toxin exposure on A549 cells [Figures 3.11 and 3.12]. For the first experiment 
exposing A549 cells to eGFPPLY, the concentration of fluorescent toxin used was 1.1µM, 
11.1µM and 111.5µM. The concentrations used should have been 1.8µM, 18.1µM and 
180.6µM to match the molarity of WTPLY at sublytic and lytic concentrations. This 
experiment however failed to correct for the eGFP molecule which accounts for 
approximately a third of the size of the eGFPPLY molecule. This experiment nevertheless 
gives an at a glance example of how a relatively low concentration of pneumolysin causes 
substantial damage to host cells leading to cell death. 
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The Δ6eGFPPLY toxoid, which was adjusted to the proper concentrations based on 
molarity, showed very different results. This toxoid lacks the ability to form functional pores 
and as a result the host cells can tolerate at least 100 times the dose of Δ6eGFPPLY without 
showing signs of cell death such as membrane blebbing and cell rounding which can be seen 
in the fully functional eGFPPLY toxin [Figure 3.12]. As mentioned above, this toxoid will 
prove valuable in distinguishing pathways initiated by cytotoxicity and those caused by 
immune reactions as the toxoid has been proven to be as immunogenic as its wild type 
predecessor (Kirkham, 2006).  
4.4 Effects of PLY on E-cadherin and F-actin in A549 lung epithelial cells 
Various studies have demonstrated pathways involved in cell to cell contacts are 
affected by the CDC toxin pneumolysin. A study involving E-cadherin was performed by 
Beisswenger et al (2007) and demonstrated colocalization between S. pneumoniae and E-
cadherin in human bronchial epithelial cells (Beisswenger, 2007). The observed 
colocalization may indicate a step in the invasion process of S. pneumoniae. 
Another study by Inoshima et al. (2011) showed degradation of E-cadherin protein 
when A549 cell monolayers were exposed to pneumolysin at concentrations of 0.1μg/ml to 
20μg/ml as demonstrated by an increase in cleavage of the C-terminal fragment of E-cadherin 
respective to increasing concentrations of WTPLY (Inoshima, 2011). Figure 3.16 shows the 
result of an experiment in which A549 cell monolayers were exposed to a sublytic, 0.1μg/ml 
concentration and a lytic, 10μg/ml concentration of pneumolysin. E-cadherin was 
subsequently probed for and in agreement with the methods in the Inoshima paper (2011). 
The lytic concentration of PLY showed cleavage of E-cadherin as demonstrated by lack of an 
E-cadherin band at 100kDa, whereas the sublytic concentration of PLY had E-cadherin bands 
were present at about the same intensity as A549 lysate controls [Figure 3.16B Lanes 1 and 4 
for A549 cells exposed to sublytic pneumolysin and lanes 6 and 7 for whole cell lysate 
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controls]. The next step would be to probe for E-cadherin using PLY time and dose curves 
paying even greater attention to equal loading in order to identify what time exposure or 
concentration is required to cleave E-cadherin. Also the non-specific cross reactivity by the 
800nm secondary antibody will have to be addressed for clarity of the results and to ensure 
that densitometry is as accurate as possible when determining band intensity. 
Immunofluorescence was also performed to try to qualitatively detect the degradation 
of E-cadherin when A549 cells were exposed to pneumolysin. The Inoshima group (2011) did 
not attempt any such qualitative experiments when testing the pore forming toxin, α-
hemolysin from S. aureus.  
Figure 3.13 shows the results of the E-cadherin immunofluorescence. There is no 
control that can be shown for comparison as this was a preliminary experiment just to see if 
E-cadherin staining could be accomplished. Figure 3.13 shows E-cadherin can be detected in 
A549 cell monolayers but the signal intensity was poor and staining was not specific to cell 
junctions as was expected and therefore the results were not suitable for further analysis. Both 
the E-cadherin immunofluorescence and the western blotting protocols will have to continue 
to be optimized before results that could help understand the interaction between PLY and E-
cadherin can be elucidated. From the results acquired so far, it is thought that the 
immunofluorescence work may require the use of a chemically conjugated version of the 
toxin as used in the Hupp et al. (2012) paper to increase the fluorescence intensity that is 
lacking in the eGFP version of the toxin as even utilizing concentrations 3x higher than the 
sublytic level did not increase toxin intensity to an adequate level. The chemical conjugation 
may also allow for further magnification of the cells without the extensive photo bleaching 
seen in the performed experiments. To aid in seeing the E-cadherin protein, the 
immunoprecipitation step performed by Inoshima et al. (2011) may have to be performed to 
concentrate the protein to a level in which the bands can be more easily distinguished 
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especially when being visualized against a high staining background on the blot. For the 
immunofluorescence, the staining protocol and or the monolayer growth may have to be 
adjusted to result in brighter staining of the E-cadherin. A different E-cadherin antibody may 
also need to be investigated as even at a high concentration only a low E-cadherin signal 
could be seen. 
The immunofluorescence targeting F-actin proved successful [Figures 3.14 and 3.15]. 
Although preliminary in nature and these experiments were designed to test the use of the 
reagents and protocols from the papers by the Iliev group (Förtsch, 2011; Hupp, 2012) before 
any multiplex staining would be attempted. The discovery of the difference in staining 
intensity between the wild type toxin conjugated to eGFP and the Δ6eGFPPLY toxoid was 
interesting as this seems to be the opposite effect as recorded in the Förtsch et al. (2011) 
paper. The results of the Förtsch et al study showed that PLY interacting with actin provided 
more intensely stained F-actin fibres than cells not treated by the toxin. Therefore, one would 
predict the wild type conjugated PLY would result in more intense F-actin staining than the 
Δ6eGFPPLY toxoid which is unable enter the cell and colocalize with actin thereby initiating 
and downstream pathways that would result in more intense fibre staining. The group also 
showed that the Δ6PLY toxoid did not cause displacement and retraction of cells that was 
seen in PLY treated cells which indicate the cells treated with PLY underwent extensive 
cytoskeletal changes to allow for the increase in focal adhesion size, migration and 
morphological changes in the astrocyte cells (Förtsch, 2011). The F-actin fibres do look more 
organized in the eGFPPLY treated cells [Figures 3.17 and 3.18]. 
 The goal of the immunofluorescence experiments was to incorporate a triplex staining 
protocol so that the eGFP conjugated PLY toxin location can be seen alongside E-cadherin 
and F-actin proteins to determine PLY effects on both of these proteins simultaneously. The 
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results above show that the F-actin component is working well and with a different E-
cadherin antibody and chemical conjugation of the toxin the triplex staining will be achieved. 
Hopefully, with higher resolution, any colocalization will be evident such as previously 
shown between PLY and F-actin in the study performed by Hupp et al. (2012). This line of 
investigation is to discern whether or not PLY interacts with these proteins directly or if PLY 
indirectly activates signalling cascades that affect the pathways these proteins are involved in 
thereby leading to bacterial invasion through tissue. 
4.5 Effect of pneumolysin and capsule on adherence of S. pneumoniae to A549 lung 
epithelial cells 
 The purpose of the adherence assay experiments was to determine the best bacterial 
model for further adherence and invasion assays. Various studies have shown that 
encapsulated S. pneumoniae have a decreased adherence and invasion compared to 
unencapsulated versions (Marriott, 2011; Beisswenger, 2007 respectively). Beisswenger et al. 
(2007) also showed that a pneumolysin negative version of S. pneumoniae did not 
significantly increase the time of transepithelial migration compared to wild type S. 
pneumoniae, indicating the PLY may not make a large contribution to tissue invasion. The 
adherence experiments performed were to test capsule and PLY under the same conditions 
and to confirm the results of the various studies while testing in the cell line of interest, A549 
lung epithelial cells to determine the best strain to use in experimentation going forward. As 
shown in Figure 3.17, D39 encapsulated, serotype 2, clinical isolate was directly compared 
with a PLY negative derivative of D39, D39 PLY STOP, in which a premature stop codon 
was created by mutation resulting in a non-functional PLY protein, FP22, a D39 mutant strain 
created and characterized by Pearce et al (2002) by insertion of a kanamycin resistance 
cassette into the capsule locus of D39 generating a nonencapsulated version of the parent type 
and R6 which is an unencapsulated, avirulent laboratory strain related to the D39 strain. This 
allowed for the testing of nonencapsulated vs. encapsulated and PLY vs. no PLY all in one. 
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The results shown in Figure 3.17 agree with the previously reported results found in the 
literature. One such result is that non-encapsulated FP22 adhered to cells slightly better than 
the encapsulated parent strain D39. The approximate percentage of adherence and relationship 
of the two strains agrees with the study performed by Marriott et al. (2011), although unlike 
the Marriott study no statistical significance was found as the p-value only reached 0.145 due 
to a higher percent adherence seen in the D39 encapsulated strain in this set of experiments. 
Another pertinent result was that the lack of PLY did not significantly affect the adherence of 
S. pneumoniae to A549 cells, which agrees with the result found when PLY and PLY 
negative strains were tested in human bronchial cells in the Beisswenger et al. (2007) paper. 
Probably the most important thing to remember is that there is a wide variance between the 
percent adherence found between the encapsulated and unencapsulated strains as well as 
between D39 and its mutants and the R6 nonvirulent D39 derivative. The difference in 
adherence between FP22 and R6, both of which are nonencapsulated is interesting and may be 
worth investigating further as to whether R6 has other factors such as an increased expression 
of adherins that give it the greater ability to adhere to A549 cells..  
 These discoveries will allow accurate planning of further experiments for not only 
what strain to use but also what parent strain should be utilized if mutants are to be generated 
in the interest of studying a specific pathway. For example, FP22 might want to be used as a 
background rather than D39 itself if investigating pathways of adherence and invasion as this 
may highlight any differences between the mutant and parent strain. As seen with D39 and 
D39 PLY STOP, the encapsulated strains ability to adhere is so close that any difference may 
be lost due to a general lack of adherence caused by the polysaccharide capsule whereas the 
difference in adherence may be found to be a statistically significant result if a more adherent 
strain was used. The effects of removing the capsule must also be considered carefully to 
determine if it is a reasonable trade off as lack of a capsule changes many aspects of bacterial 
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behaviour and the host’s behaviour to the organism. Van der Windt et al. (2012) showed that 
a unencapsulated D39 had a greater resistance to killing by neutrophil proteases than the 
encapsulated D39 which combined with their increased ability to adhere may be why more 
unencapsulated S. pneumoniae are found on mucosal surfaces than encapsulated strains. 
4.6 Host-Pathogen Interactions and Generation of a Fluorescently Tagged Pneumolysin 
 The applications of green fluorescence protein (GFP) have been widely used in protein 
localisation, cell labelling, DNA and RNA labelling and promoter tracking (Chudakov, 2010). 
Until recently, the use of fluorescence in the study of S. pneumoniae has been limited. This 
may be due to the fact that it is notoriously hard to visualize GFP in S. pneumoniae due to 
their preference for low oxygen and their creation of acidic environments, both of which 
negatively affect the performance of GFP (Acebo, 2000). A few recent studies in the 
pneumococcal field have begun to develop molecular toolboxes that include fluorescence in 
the study of pneumococci (Eberhardt, 2009; Henriques, 2013; Holmes, 2012). One such 
study, Eberhardt et al. 2009, has been investigated for possible use in the current study. Of the 
two plasmids described in this study, the plasmid pJWV25 is most relevant as it allows 
construction of an N-terminal fusion between a chosen protein to a high intensity variant of 
GFP, called GFP+. The link to the N-terminal end of PLY is crucial for use in this project as 
any large proteins such as GFP+ cannot be linked to the C-terminal domain of PLY as the C-
terminal domain is the essential in the toxin binding to target cells and therefore a large 
protein would likely interfere with any toxin-host interaction and downstream signalling 
cascades which are the main focus of this project (Marriott, 2008). Also the utilization of a 
double crossover event to integrate the fusion gene into the pneumococcal chromosome is 
advantageous as it allows for the generation of a more stable mutant which expresses the 
fusion protein (Eberhardt, 2009). The plasmid pJWV25 contains a zinc inducible promoter 
that was originally introduced into the plasmid pMP2-2 (Kloostermann, 2007) which is the 
Culverhouse 68 
 
precursor of pJWV25. Although an inducible promoter is potentially useful, the concentration 
of zinc (0.15mM) required to initiate the production of the GFP+ is high enough to be lethal 
mammalian cells and is therefore not suitable for studies of host-pathogen interactions. For 
use in this project, a new promoter would have to be inserted into the pJWV25 plasmid to 
replace the zinc inducible promoter. The promoter chosen for this will be a constitutive 
promoter, P2, isolated and characterized by a member of the Pneumococcal Research Group 
(Herbert, 2012). Although this promoter is not inducible, it will allow constitutive expression 
of fusion constructs for studies involving the localisation of PLY in cell and animal systems. 
The introduction of pJWV25 into S. pneumoniae was attempted for a number of 
reasons. This plasmid was designed in the Veening lab and needed to be tested in the 
pneumococcal strains of interest, D39 and TIGR4. The S. pneumoniae pJWV25 clone would 
give a GFP+ mutant that would fluoresce when induced with zinc. Although the zinc 
concentration required to induce protein production is too high to be used with mammalian 
cells, this experiment was performed to ensure the protein induction system designed in the 
plasmid worked with the strains of interest before switching out the promoter for P2 which 
could be utilized in a live cell system. The constructs could also be used in pneumolysin 
localisation studies with respect to bacterial cells alone as the method of release of PLY from 
the bacterial cell is still in unclear. The results show a screening PCR using primers designed 
in Eberhardt et al. 2009 that will amplify a section of pJWV25 if it is present within the DNA 
of interest (Eberhardt, 2009). Figure 3.17 shows that a product was amplified from the 
chromosome of D39 S. pneumoniae. This is a good indication that the transformation of the 
plasmid into S. pneumoniae was successful. However, to confirm this observation sequencing 
and possibly fluorescence microscopy should be done to further verify these results.  
Other possible fluorescence constructs were also considered as described by 
Henriques et al. 2013. This study illustrates various florescent constructs that could be used as 
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an alternative to GFP to counteract the difficulties with using GFP in S. pneumoniae studies 
as described above due to the organism favouring low oxygen environments. The other 
possible fluorescent fusions that could be used were mCherry, Citrine and CFP which would 
be expressed via a plasmid (Henriques, 2013). The reason the Eberhardt (2009) GFP+ 
construct was ultimately pursued was due to the strength of the plasmid construction with the 
favourable flexible linker region and double crossover event to incorporate the fluorescent tag 
into the genome which would result in a more stable mutant as S. pneumoniae frequently 
favours genetic recombination and often ejects plasmids. 
The growth curves with CDM were to test that the defined media allowed the growth 
of TIGR4 and D39. These two strains were chosen as they are well characterized in various 
assays throughout literature. The results [Figure 3.19] show the successful growth of these 
strains in CDM, although at a lesser degree than BHI, in a water bath culture. However, the 
growth of these strains was not successful in the 96 well plate during a growth curve 
experiment. A possible reason for the lack of growth could be due to the volume in which 
these strains were allowed to grow for the 18 hour period. There may be some difference in 
the nutrient proportions when scaled down to 200μl for use in a 96 well plate that are 
corrected in larger volumes such as the 10ml universals. There may also be something said for 
the evaporation effects that occur in plates that do not in closed universals. This line of 
thought is however pure speculation and if in the future CDM is to be used in 96 well format 
for multiplex testing it will have to be further investigated. For the purpose of this project, 
CDM was mainly to be used for microscopy work and will be used for microscope slides or in 
35mm dishes to prevent the auto-fluorescence that occurs in BHI. Hopefully at the volumes 
required for these experiments the lack of growth will not be seen and the benefits will 
therefore outweigh the negatives of utilizing this media. 
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4.7 Summary 
 This project aimed to study some of the interactions between the pore forming toxin 
pneumolysin and human host cells. This study was focused on the studying the interactions 
with regards to the epithelial cell barrier to further understand how S. pneumoniae invades the 
host changing it from a commensal organism to an invasive one. The experiments in this 
study were designed to first create an optimized testing environment then to test the 
interaction of PLY with host cell epithelial barriers and the pathways that regulate them.  
Chemically defined media was prepared and successfully tested for later use in 
fluorescent microscopy studies to reduce background fluorescence that occurs with standard 
media. Optimization of a plasmid for expression of a fluorescently conjugated pneumolysin 
produced in S. pneumoniae rather than a Gram negative equivalent was begun for later use in 
localisation studies to see if PLY co-localises or directly interacts with any epithelial proteins. 
Adherence experiments showed that the optimal background strain for investigation into 
invasion would be one that is encapsulated as the adherence to the host is much greater than 
strains that have a polysaccharide capsule. The preliminary fluorescence experiments led to 
the successful staining of F-actin fibres and also determined the highest concentration of PLY 
that could be used before lytic effects would occur in the host cell. 
 There were difficulties in this project such as finding a suitable E-cadherin antibody 
that would be able to fluoresce without significant photo bleaching as high magnification was 
to be used. Also cloning the pJWV25 plasmid into the desired strains of S. pneumoniae 
successfully proved difficult as spontaneous antibiotic resistant mutants were often the result 
rather than the actual incorporation of the plasmid. However, despite the issues a foundation 
for further successes seems to have been laid and with further time and resources more 
definitive and progressive results would have hopefully been on the horizon. 
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4.8 Future Work 
 The experiments completed during the course of this master’s project open up a 
variety of future work that can build upon the foundation of the results shown discussed in 
this thesis.  
The purification of the proteins and the establishment of sublytic concentrations allow 
for future cell based assays. A more in depth investigation of apoptotic and repair pathways 
triggered by sublytic vs lytic amounts of pneumolysin can be designed and carried out. Also 
one can build upon the F-actin and E-cadherin work shown in this paper and continue with 
time and dose curves to see what concentration of pneumolysin causes the degradation of E-
cadherin and if pneumolysin effects F-actin in a similar way. Co-localization studies can also 
be pursued with further adjustments to the E-cadherin immunofluorescence as the F-actin 
staining proved successful and as there is a large successful batch of Δ6eGFPPLY already 
available only a batch of eGFPPLY would be required to apply fluorescent toxin to the cell 
monolayers. The CDM media can be applied to perhaps employ any live cell imaging to avoid 
auto fluorescence. 
The adherence assays showed that a noncapsular version of D39 could be used to 
investigate transepithelial migration thru invasion assays. Although the adherence assays 
indicated PLY does not play a major role in adherence it may be that it plays a greater role in 
invasion of epithelial barriers. 
The pJWV25 plasmid work could also be pursued further to allow for a constitutive 
promoter of fluorescently tagged PLY in its natural host which would be useful for any 
experiments utilizing live bacteria which would create a more realistic experimental model 
than using protein purified in a Gram negative bacterium.  
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Appendix I Recipes 
 
CDM Buffer 
Chemical Amount 
Na-B-glycerophosphate 21 g 
KH2PO4 1 g 
(NH4)3 citrate 0.6 g 
Na-acetate 1 g 
Dissolved in 800 mL  dH2O, pH 6.4 with 1 M HCL 
 
Metal Mixture 
Chemical Amount 
MgCl2 
.
 6H2O 4 g 
CaCl2 0.74 g 
ZnSO4 
.
 7H2O 100 mg 
CoCl2 
.
 6H2O 50 mg 
CuSO4 
.
 5H20 2 mg 
Dissolved in 200 mL dH2O, pH 7.0 
 
Vitamin Mixture 
Chemical Amount 
Pyridoxal-Cl 40 mg 
Thiamine Cl2 20 mg 
Riboflavin 20 mg 
Ca-pantothenate 20 mg 
Biotin 2 mg 
Folic acid (stored in dark) 20 mg 
Niacin amide 20 mg 
Dissolved in 200 mL dH2O, pH 7.0 
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Complete DMEM 
176 ml Dulbecco’s Modified Eagle 
Medium (Sigma) 
20 ml Fetal Bovine Serum (Gibco) 
2 ml Penicillin/Streptomycin (Sigma) 
2 ml L-glutamine (Sigma) 
 
Lysis buffer (E-cadherin experiments) 
modified from Inoshima et al 2011 
10mm Tris pH 7.4 (Fisher Scientific) 
150mM NaCl (VWR) 
2mM EDTA (Fisher Scientific) 
0.5% IGEPAL CA-630 (Sigma) 
1% Triton X-100 (Sigma) 
cOmplete EDTA free protease inhibitor 
cocktail tablet (Roche) 
up to 50 ml in dH2O 
 
TBST 
20mM Tris (Fisher Scientific) 
137mM NaCl (VWR) 
0.1% Tween (Sigma) 
pH 7.6 
 
High salt TBST 
145ml of 5M NaCl (VWR) 
Up to 2L of TBST 
 
TBS 
20mM Tris (Fisher Scientific) 
137mM NaCl (VWR) 
pH 7.6 
 
4x Reducing SDS PAGE sample buffer 
3.75ml 1M Tris-HCl pH 6.8 
6ml glycerol (Fisher Scientific) 
1.2g SDS (Fisher Scientific) 
0.93g DTT (Sigma) 
6mg bromophenol blue (BDH 
Biosciences) 
Up to 15ml with dH2
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Appendix II Strains Used in this Study 
 
D39 = serotype 2 S. pneumoniae strain used in the 1928 experiment by Frederick Griffith and 
Avery et al 1944.  
D39 PLY STOP = D39 mutant in which the PLY gene has a premature stop codon resulting 
in a non functional toxin created by Graeme Cowan (2006) for use in his PhD thesis. This 
was accomplished using the Janus technique described in Sung et al. 2001. 
D39 FP22 = acapsular D39 created by Pearce et al. 2002 by insertion of a Kanamycin 
cassette deleting the capsule locus 
R6 = laboratory, acapsular, avirulent descendent of D39 serotype 2 strain used in the study by 
Avery et al 1944 
TIGR4 = Serotype 4 clinical isolate of S. pneumoniae. Strain was isolated in the study by 
Aaberge et al. 1995. 
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